

I. Biographical and Bibliographic Information

John P. Cooke MD PhD
Professor, Division of Cardiovascular Medicine
Associate Director, Stanford Cardiovascular Institute
Stanford University School of Medicine
300 Pasteur Drive, Stanford, CA 94305-5406
Phone: 650 725-3778
john.cooke@stanford.edu

Academic history:

1. Colleges and universities attended, degrees received, dates:

9/1972-6/1976	B.A.	Cornell University, Ithaca, NY
9/1976-6/1980	M.D.	Wayne State University, Detroit, MI
1/1983-6/1985	Ph.D.	Mayo Graduate School of Medicine, Rochester, MN

2. Post-doctoral and residency training:

6/1980-12/1982	Resident in Internal Medicine, Mayo Graduate School of Medicine
1/1983-6/1985	Research Fellow, Department of Physiology and Biophysics, Mayo Graduate School of Medicine, Rochester, MN
1/1985-12/1986	Fellow in Cardiovascular Medicine, Mayo Graduate School of Medicine

3. Board eligibility or boards passed, with date(s):

1984	American Board of Internal Medicine, Internal Medicine
1986	American Board of Internal Medicine, Cardiovascular Disease
2006	American Board of Vascular Medicine, Vascular Medicine

Employment history.

Academic positions:

1/1987-4/1987	Instructor Mayo Graduate School of Medicine, Rochester, MN
4/1987-7/1990	Assistant Professor of Medicine Harvard Medical School, Boston, MA
8/1990-6/1995	Assistant Professor of Medicine Stanford University School of Medicine
6/1995-5/2003	Associate Professor of Medicine (with tenure) Stanford University School of Medicine

5/2003- Professor of Medicine (with tenure)
 Stanford University School of Medicine
 2008-Present Associate Director, Stanford Cardiovascular Institute

Non-Academic positions:

1983-1984 Emergency Room Physician, St. Joseph Mercy Hospital, Mason City, IA
 1983-1985 Instructor and faculty member, AHA Advanced Cardiac Life Support
 Mayo Clinic
 1985-1986 Lecturer, Cardiovascular Physiology, Mayo Graduate School of Medicine
 1987-1988 Tutorial in Physical Diagnosis Skills, Harvard Medical School
 1987-1990 Attending Physician, Division of Vascular Medicine and Atherosclerosis
 Brigham and Women's Hospital, Boston, MA
 1989-1990 Lecturer, Cardiovascular Pharmacology, Massachusetts College of
 Pharmacy
 1990-present Attending Physician, Stanford University Hospital, Stanford, CA
 1990-present Lecturer, Cardiovascular Physiology, Stanford University
 1999-2005 Director, Stanford Guidant Lecture Series

Public and professional service:

International committees and task forces:

1991-2000 European Working Group - Medical Angiology (U.S. Representative)
 1991-2003 Society for Vascular Medicine and Biology: Trustee
 1992-1995 International Union of Angiology: National Delegate
 1993-1996 Committee member, International Task Force on Venous Insufficiency
 1995-1997 European Working Group on Medical Angiology, Committee Member
 1995-1998 Executive Board of International Union of Angiology
 2002- Advisor to the President, International Union of Angiology
 2002 External Reviewer for Research Study Section, Research Funding and Policy
 Division Health Research Board, Dublin, Ireland
 2003 Scientific Organizing Committee for "Vascular NO: from Bench to Bedside"
 Hannover Germany Mar 11-13 2004
 2004 Chairman, Scientific Organizing Committee for "2nd International Meeting on
 ADMA", New Orleans LA November 2004
 2005 External Reviewer, Italian Association for Cancer Research, March 2006
 2006 External Reviewer, British Heart Foundation, March 2006
 2007- External Reviewer, Medical Research Council
 2010 Co-Chair, 5th International Symposium on ADMA "ADMA: Bench to bedside"

2011 and back; Exploring new paradigms". Chicago, IL. Nov 11-12, 2010.
 Vascular Regenerative Medicine Network, Medical Research Council (PI:
 Professor Paolo Madeddu, Head of Regenerative Medicine, Bristol Heart
 Institute, University of Bristol).

National committees and task forces:

1991 National Heart, Lung and Blood Institute: Working Group on Non-Coronary
 Cardiovascular Disease and Exercise. *Physical Activity and Cardiovascular
 Health: Special Emphasis on Women and Youth.*

1991-1999 Trustee, Society for Vascular Medicine and Biology (elected position)

1992 National Heart, Lung and Blood Institute: Special Emphasis panel.
Peripheral Arterial Disease Pilot Study.

3/1993 National Heart Lung and Blood Institute: Special Study Section meeting.
Pathology A.

3/18/1993 National Heart, Lung and Blood Institute: Special Emphasis panel. *Vascular
 Disease Academic Award.*

1993-1997 Intersocietal Commission for the Accreditation of Vascular Laboratories:
 Board of Directors (ACC)

1995 National Heart, Lung & Blood Institute: Special Emphasis Panel, Vascular
 Disease Academic Award

1997-1999 Test Material Development Committee, U.S. Medical Licensing Examination
 (National Board of Medical Examiners)

1997-2000 American College of Cardiology: Member, Peripheral Vascular Disease
 Committee

1998-2003 Metabolism Study Section NIH, ad hoc reviewer

2000-2002 Clinical Research Review Committee

10/2001 Consultant, NHLBI Vascular Medicine Working Group

10/2001 Reviewer, NHLBI SCOR on Molecular Medicine and Atherosclerosis

7/2002 Reviewer, NIH Office of Dietary Supplements, Annual Bibliography of
 Significant Advances in Dietary Supplement Research 2001

2002-05 Councilor, North American Vascular Biology Organization (elected position)

2002 Member, Steering Committee for the Critical Limb Ischemia Research
 Consortium

2003-05 Member, Young Investigators Award Committee, American College of
 Cardiology

2003 Chair, Young Investigators Award Competition for Molecular and Cellular
 Cardiology

2003 Member, National Steering Committee for REACH Registry (Reduction in
 Atherothrombosis for Continued Health)

2003-05 President-Elect, Society for Vascular Medicine and Biology

2004 Working Group Member, Methods and Biomarkers to assess Reductions in
 Tobacco Toxin Exposure. Washington, DC, February 28, 2004 sponsored by
 the NIH, NCI, NIDA, NIAAA.

2004 Peer reviewer, ACC/AHA Guidelines for the Management of PAD

2005-06 Writing committee, American Board of Vascular Medicine

2005-07 President, Society for Vascular Medicine and Biology

2005-07 Director, American Board of Vascular Medicine

2006 Chair, Committee for the Douglas P. Zipes Distinguished Young Scientist
 Award of the American College of Cardiology

2006-08 Chair, Young Investigators Award Committee, American College of

	Cardiology
2008	Member, K99/R00 Advisory Panel, Sandra Wells PhD (U. of MT Postdoctoral Fellow)
2008-09	Member, International Scientific Advisory Board, XXIInd Congress of the International Society on Thrombosis and Haemostasis
2009	NHLBI reviewer for RFA "Cardiac Translational Research Implementation program (C-TRIP)
2010	Ad Hoc Search Committee member for the Division of Hematology/Oncology, Harvard Medical School
2012-	Member, Cardiovascular Cell Therapy Research Network, Executive Committee
2012-	Member, Cardiovascular Cell Therapy Research Network, Publications and Presentations Subcommittee
2012-	Member, External Advisory Committee, T32 Training grant, Immunology
2013-	Member, Search Committee for Editor-in-Chief, Journal of the American College of Cardiology

Local committees and task forces:

1990-present	Director, Section of Vascular Medicine
1990-1991	Advisory Committee, Division of Cardiovascular Medicine, Stanford University School of Medicine
1990-1995	Vascular Working Group, Department of Medicine Vascular Center Committee Stanford University Hospital
1990-1996	Clinical Quality and Standards, Division of Cardiovascular Medicine, Stanford University School of Medicine
1991-1996	Clinical program Development Committee
1991-2000	Medical Student Research Symposium, Organizing Committee
1992-1999	Director, Stanford University Lymphedema Center
1993	Chairman, Local Organizing Committee, 3 rd International Symposium on Endothelial Factors
1995	Chairman, Local Organizing Committee, 4 th International Symposium on Endothelial Factors
2001-present	Member, Biodesign Committee, Stanford University School of Medicine
2001-present	Reviewer, Seed Grant program, Stanford Office of Technology Licensing
2001	Chairman, Organizing Committee for Bay Area Conference on Controversies in Cardiovascular Nutrition.
2002-present	Member, Review Committee, Dean's Postdoctoral Fellowship
2001	Chair, American Heart Association Roundtable for Student Research
2002	Member, American Heart Association Student Research Committee
2003-present	Dept of Medicine Academic Appointments and Promotions Committee,
2004-2006	Co-Chair, American Heart Association Young Investigators Forum
2005-present	Member, Executive Committee, Stanford Cardiovascular Institute
2006	Scientific advisory Board, Sports Medicine Center, Stanford University
2007-present	Associate Director, Education and Training, Stanford Cardiovascular Institute
2008	Member, Search Committee for Director of Quantitative Sciences Center
2008	Research Space Planning Committee, Dept of Medicine, member
2009	Examining committee, PhD candidate William Yang, Dept. of Bioengineering Chair, University Oral Examination, PhD candidate Hyeonsoo Chang
2009-present	Member, Postdoctoral Research Committee, Chemical and Systems Biology

2010-present	Member, Development Committee, Stanford Cardiovascular Institute
2011	Member, External Advisory Committee, T32 Training program in Vascular Biology, Indiana University
2011	Reading committee, PhD candidate Edwina Shui Lai, Dept. of Chemical Engineering
2011	Member, Stanford-Coulter Oversight Committee
2012	Reader, PhD Thesis Defense, Edwina Lai, Dept of Chemical Engineering
2013	Member, Medical School Cores Advisory Board

Community Work

2003-05	Faculty attending, Arbor Free Clinic (medical-student run, faculty-supervised free clinic for homeless and uninsured)
2012	Pilot test contributor, Understanding Science Project (WestEd) for the curriculum entitled: <i>Making Sense of SCIENCE: Matter for Teacher of Grades 6-8.</i>

Editorial Experience:Editorial Boards

1986-1987	Editor, Vascular Medicine Syllabus, for Mayo Clinic Medical residents
1990-1991	Editorial Board, <i>Journal of Vascular Medicine and Biology</i>
1992-1993	Assistant Editor, <i>Journal of Vascular Medicine and Biology</i>
1993-1995	Consultant Editor, <i>Vascular Medicine Review</i>
1993-2009	Senior Associate Editor, <i>Journal of Vascular Medicine and Biology</i>
1993-present	Editorial Board, <i>Circulation</i>
1996-present	Editorial Board, <i>Journal of Cardiac Disease Prevention</i>
1997-1999	Editorial Board, <i>Journal of the American College of Cardiology</i>
1997-present	Editorial Board, <i>Journal of the International Society of Cardiovascular Pharmacotherapy</i>
1999-present	Editorial Board, <i>Cardiovascular Drugs and Therapy</i>
2000-present	Editorial Board, <i>American Journal of Cardiovascular Drugs</i>
2001-present	Editorial Board, <i>Korean Journal of Cardiovascular Diseases</i>

ReviewerScientific Journals

American Heart Journal
American Journal of Physiology
Arteriosclerosis
Atherosclerosis
Biochemical Pharmacology
Blood Vessels
Canadian Journal of Physiology
Circulation
Circulation Research
Endothelium
Hypertension
International Journal of Cardiology
Journal of the American College of Cardiology
Journal of the American Society of Nephrology

Journal of Cardiovascular Pharmacology
Journal of Clinical Investigation
Journal of Lipid Research and Pharmacology
Life Sciences
Nature Medicine
New England Journal of Medicine
Vascular Research
Nitric Oxide: Biology & Chemistry
Science

Abstract reviewer for Scientific Sessions

1991-present Grader of Scientific Abstracts, American College of Cardiology
 Annual Scientific Session
 1991-present Grader of Scientific Abstracts, American Heart Association
 Scientific Session
 1995-present Grader of Scientific Abstracts, Society of Vascular Medicine and Biology
 Scientific Session

Moderator/Chair Scientific Sessions

1991-present Moderator, Annual Scientific Sessions, American Heart Association
 1991-present Moderator, Annual Scientific Sessions, American College of Cardiology
 1992-present Moderator, Annual Scientific Sessions, Society for Vascular Medicine and
 Biology
 5/1/1993 Chairman, Featured Research Category
 (Atherosclerosis and Vascular Biology)
 American Federation of Clinical Research
 1998-present Judge, ACC Young Investigators Awards Competition
 1998-present Moderator, Scientific Sessions International Union of Angiology
 2006-2009 Chair, Young Investigators Award Committee, ACC

Post-degree honors and awards

Professional associations and learned societies:

1980-1987 Zumbro Valley Medical Association; Minnesota Medical Association
 1983-1986 Delegate, Minnesota Medical Association
 1983-1986 Membership Committee, Zumbro Valley Medical Society
 1987-1989 Massachusetts Medical Society
 1989-present Founder of the Society for Vascular Medicine and Biology,
 Officer or Trustee 1989-2009.
 1992 National Delegate, International Union of Angiology
 1997 International Advisory Committee, Executive Board
 18th World Congress of the International Union of Angiology
 1980-1990 American Medical Association
 1987-2005 American Federation for Clinical Research
 1990-2006 International Union of Angiology
 1984-2009 American College of Cardiology
 1988- American Heart Association

1989- Society for Vascular Medicine
 2010- International Society of Stem Cell Research
 2010- American Association of Physicians
 2010- International Society for Stem Cell Research

Honors and awards:

1983 Clinician Investigator Award, Mayo Clinic, Rochester, MN
 1984 1st place, Am. College of Physicians, Associates paper competition, Minn.
 1985 Merck Fellowship Award, American College of Cardiology
 1988 Milton Award, Harvard Medical School
 1989 Founding member, Society for Vascular Medicine and Biology
 1990 First place, Young Investigator Competition, Am. College of Cardiology
 1990 Henry Christian Award, American Federation for Clinical Research
 1990 Fellowship, Council on Circulation, American Heart Association
 1995 Pfizer Visiting Professor, University of South Carolina School of Medicine
 1995 AHA-Sanofi Winthrop Grant-in-aid Awardee
 1995 Established Investigator Award, American Heart Association
 2000 Teaching Award, Department of Medicine, Stanford University
 2001 Named as one of the "Best Doctors in the Bay Area", San Francisco
 Magazine, Jan 2003 issue(based on a survey of medical professionals)
 2003-05 President-Elect, Society for Vascular Medicine and Biology
 2005 "Leadership in Education", awarded by the Dean's office for substantial
 contributions to the educational programs of Stanford University School of
 Medicine
 2005-07 President, Society for Vascular Medicine and Biology
 2007 *Annual Bibliography of Significant Advances in Dietary Supplements
 Research*, Office of Dietary Supplements, NIH. Wilson AM et al, *Circulation*
 2007; chosen as one of the top 25 papers of 2007
 2008 Best Research Award (category: Vascular Medicine). Annual award of the
 PAD Coalition.
 2008 Master of the Society for Vascular Medicine
 2010 AACC Outstanding Speaker Award

Research Grants:

Past Research Grants:

1983-1984 General Mills
 General Mills Fellowship Award for Research in Cardiovascular Disease
 1985-1986 Merck
 American College of Cardiology Fellowship Award
 1988-1990 American Heart Association (Massachusetts Affiliate)
 Principal Investigator
 "Endothelial function in human umbilical arteries."

- 1990-1993 American Heart Association (National)
Principal Investigator
"Role of Nitric Oxide in Atherosclerosis."
- 1990-1991 Scleroderma Federation
Principal Investigator
"Alpha-2 adrenoceptors and thermoregulation."
- 1990-1991 Institute of Biological & Clinical Investigation
Principal Investigator
"Endothelial dysfunction in atherosclerosis."
- 1991-1994 University of California
Co-Principal Investigator
Tobacco-Related Disease Research Program
"Angiotensin II, endothelial dysfunction and atherosclerosis."
- 1991-1992 Director's Research Fund Program in Molecular and Genetic Medicine
Co-Principal Investigator
"Reversal of endothelial dysfunction and regression of atherosclerosis."
- 1991-1995 Vascular Disease Academic Award
Principal Investigator
NHLBI # 1K07HCO 2660
- 1992-1998 National Institute of Health; HL48638-01 (PPG)
Principal Investigator
"Project II, Endothelial K⁺ and Ca⁺⁺ Channels and Response to Flow"
Pathology of Vascular Remodeling (VJ Dzau, program director)
- 1992-1998 National Institute of Health: HL48638-01 (PPG)
Principal Investigator
"Project III, Exercise-Induced Vascular Remodeling and Reactivity"
Pathology of Vascular Remodeling (VJ Dzau, program director)
- 1993-1994 Merck, Sharp & Dohme
Principal Investigator
"Effects of Felodipine on Vascular Structure and Function in
Hypercholesterolemic Rabbits."
- 1993-1995 American Heart Association (California Affiliate)
Principal Investigator
Grant-in-Aid #93-252
"Modulation by NO of Platelet-Vessel Wall Interactions."
- 1993-2007 National Institute of Health; T32 HL007708
Principal Investigator
Vascular Medicine & Biology Training Grant.
- 1994-1995 Upjohn

- Principal Investigator
"Ramipril Normalizes Vascular Reactivity and Structure Following Balloon Angioplasty."
- 1994-1995 Abbott Laboratories
Principal Investigator
"Alteration of Nitric Oxide Synthase Isoforms During Atherogenesis."
- 1994-1997 Sigma-Tau Pharmaceuticals
Principal Investigator
"Safety and Efficacy of Propionyl L-Carnitine in Peripheral Arterial Disease (Intermittent Claudication)."
- 1995-1997 Schwarz Pharmaceuticals
Principal Investigator
"Efficacy and Safety of Vasoprost (Alprostadil) in the Treatment of Patients with Severe Intermittent Claudication due to Peripheral Arterial Occlusive Disease (PAOD)."
- 1995-1997 Hoechst Marion Roussel
Principal Investigator
"Dose-Response Evaluation of Beraprost Sodium IR Tablets in the Treatment of Intermittent Claudication."
- 1996-1997 Peninsula Community Foundation, Palo Alto, CA
Principal Investigator
"Raynaud's Syndrome and Vascular Nitric Oxide Activity."
- 1996-1997 Scios
Principal Investigator
"Phase II Study of FIBLAST® Trafermin in Treatment of Intermittent Claudication."
- 1996-1997 Scios
Principal Investigator
"Phase II Study of FIBLAST® Trafermin in Treatment of Critical Leg Ischemia."
- 1996-2000 American Heart Association (National)
Principal Investigator
"Anti-Atherogenic Effects of EDRF: Effects of MCP-1."
- 1996-2001 National Institute of Health; HL08506-34
Principal Investigator
"Lipemia-Carbohydrate and Glyceride Metabolism."
- 1997-1998 Syntex Pharmaceuticals
Principal Investigator
"Safety and Efficacy of Ranolazine in the Treatment of Intermittent Claudication."

- 1997-1999 Pharmacyclics
Principal Investigator
"Phase I Study to Assess the Safety and Efficacy of Lutetium Texaphyrin
in Treatment of Peripheral Arterial Disease in Humans."
- 1998-1999 Sterling Winthrop
Principal Investigator
"Clopidogrel vs. Aspirin in Patients at Risk of Ischemic Events (CAPRIE)."
- 1999-2000 CardioVasc, Inc.
Co-Principal Investigator
"Enhancement of Endothelial Surfacing by the CardioVasc Peptide."
- 1999-2001 Peninsula Community Foundation
Principal Investigator
"Therapeutic Modulation of the NO Synthase Pathway for Raynaud's
Phenomenon."
- 1999-2000 Geron Corporation
Principal Investigator
"Response to Shear Stress of Normal, Senescent and Immortalized
Endothelial Cells."
- 1999-2000 Cellgate, Inc.
Principal Investigator
"Hepta-arginine (R7) Mediated Antisense Oligonucleotide Delivery in Vein
Graft Atherosclerosis."
- Dean's Office (OTL Fund)
Principal Investigator
"Nicotine for Therapeutic Angiogenesis."
- 1999-2000 Sanofi
Principal Investigator
"The PARTNERS Study: Screening for Peripheral Arterial Disease."
- 1999-2000 Dean's Office (OTL Fund)
Principal Investigator
"Argininated Inositol: A Novel Agent for Cardiovascular Health."
- 1999-2001 Tobacco-Related Disease Research Program, University of California
Award #7RT-0128
Principal Investigator
"Mechanisms by which Tobacco Accelerates Atherogenesis."
- 2000-2006 National Institute of Health; RO1 HL63685
Principal Investigator
"Therapeutic Modulations of the NO Synthase Pathway."
- 2001-2003 Phillip Morris External Research Grant Program
Principal Investigator

- "Nicotine enhances vessel formation."
- 2001-2004 National Institute of Health; R01 HL
Co-investigator
"Gingko biloba: its effects on vascular function and structure in PAD."
- 2001-2005 National Institute of Health; R01 HL
Co-investigator
"Depression and Cardiovascular function."
- 2001-2006 National Institute of Health; PO1 AI50153
Project Leader: "Role of CMV and Derangement of the NO Synthase Pathway."
- 2002-2005 Tobacco-Related Disease Research Program, University of California
Principal Investigator
"Pathological Angiogenesis and Genetic Determinants"
- 2003-2008 National Institutes of Health, 1R01 HL075774
Principal Investigator
Genetic Determinants of Peripheral Arterial Disease.
- 2004-2007 Philip Morris External Research Grant Program
Principal Investigator
"nAChR-mediated Angiogenesis: Interactions with known angiogenic pathways"
- 2005-2010 Genzyme
Principal Investigator
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-selection Study of Ad2/Hypoxia Inducible Factor (HIF)-1 α /VP16 in Patients with Intermittent Claudication.
- 2005-2009 National Institutes of Health, 1R01 CA098303
Principal Investigator
Signal-transduction of endothelial nAChR in angiogenesis.
- 2005-2008 Univ of California Office of the President, Tobacco-Related Disease Research Program (14RT-0169).
Principal Investigator
"SHS Exacerbates Cerebral Ischemia: Endothelial Mechanism."
- 2005-2008 Tobacco-Related Disease Research Program, University of California
Principal Investigator
"Second hand smoke exacerbates cerebral ischemia: Endothelial mechanisms"
- 2006-2007 University of California office of the President
Principal Investigator
Mechanisms of Tobacco-Induced Retinal Neovascularization.

- 2006-2008 National Institutes of Health, 1 R21 HL085743
Principal Investigator
ADMA: An Endogenous Inhibitor of ESC Differentiation and EC regeneration.
- 2006-2008 National Institutes of Health, R21 HL085743
Principal Investigator
ADMA: An Endogenous Inhibitor of ESC Differentiation and EC regeneration.
- 2006-2011 National Institutes of Health, 5P50 HL083800
Project director
AAA Disease: Mechanism, Stratification and Treatment.
- 2007-2009 California Institute for Regenerative Medicine, RS1-00183
Principal Investigator
EC Regeneration in cerebrovascular ischemia: role of NO
- 2008-2009 Colorado Prevention Center (Prime Diffusion Pharm)
Principal Investigator
Phase I/II randomized clinical trial of trans sodium crocetin therapy for PAD.
- 2008-2009 Genentech, Inc
Principal Investigator
Role of Asymmetric Dimethylarginine in Cardiovascular disease and inflammation.
- 2008-2010 National Institutes of Health, 5R01 CA098303
Principal Investigator
Signal-transduction of Endothelial nAChR in Angiogenesis.
- 2009 American Heart Assn
Principal Investigator
Nuclear Reprogramming for Vascular Regeneration
- 2009-2010 University of California, San Francisco, 4588SC
Collaborator
Multifactor Risk Reduction for Optimal Management of PAD
- 2009-2010 The Wallace H. Coulter Translational Research Grant Program
Efficient and Safe Methods for Nuclear Reprogramming (coPI)
- 2009-2010 Johnson & Johnson
Principal Investigator
Efficacy of ATRM Cell transplantation in a mouse model of PAD
- 2009-2011 University of California Office of the President, 18XT-0098
Principal Investigator
An atypical nicotine receptor: Target for anti-angiogenics: Mechanisms.

- 2009-2011 National Institutes of Health, 1RC2 HL103400
Principal Investigator
NCE-based strategy for nuclear reprogramming regenerative medicine.
- 2010-2011 Cyokinetics
Principal Investigator
A Phase II, double-blind randomized, placebo-controlled, three-way
crossover pharmacokinetic and pharmacodynamic study of CK 2017357
in patients with claudication.
- 2010-2012 Pluristem
Principal Investigator
Safety of Intramuscular Injection of Allogeneic PLX-PAD Cells for the
Treatment of Critical Limb Ischemia”

Current Research Grants:

- 04/01/07 - 03/31/13
NHLBI 5K12 HL087746 (PI)
“Stanford Career Development in Vascular Medicine”
\$618,011/yr
- 04/15/09 - 11/30/15
NHLBI 1R01 HL093172 (collaborator)
“Molecular Imaging of Targeted Cardiac Gene Therapy”
\$500,000/yr
- 09/30/09 - 04/30/16
NHLBI 1U01 HL100397 (PI)
“Basic and Translational Research of iPSC-Based Hematologic and Vascular Therapies”
\$750,000/yr
- 02/01/10 - 01/31/15
NHLBI T32 HL098049 (PI)
“Mechanisms and Innovation in Vascular Disease”
\$262,819/yr
- 09/30/11 - 08/31/15
NEI 1R01 HL02060901 (PI)
“The Role of the Nicotinic Cholinergic Pathway in Retinopathy of Prematurity”
\$330,000/yr
- 04/01/12 - 03/31/19
1UM1 HL113456 (PI)
“Cell Characterization and Imaging for Regenerative Therapies in Ischemic Diseases”
\$362,550/yr
- 09/30/12 - 08/31/16

1R01 AR063963 (co-investigator)
 NIH Director's Transformative Research Award
 "Telomere extension using nucleoside-modified mRNA and exosomes for DMD."
 \$537,960/yr

10/01/12 – 04/30/14
 NHLBI SPO109490 (PI)
 "RNAcore for the Progenitor Cell Biology Consortium"
 \$75,000/yr

Publications

(375 publications, excluding abstracts, with over 19,500 citations, Web of Science, 1-30-13; h-index 75)

Original research articles [200]

1. **Cooke JP**, Winkelman RK: Response of bullous congenital ichthyosiform erythroderma to high-dose vitamin A. *Cutis*. 1982 Jan;29(1):44-6
2. Thomas JR 3rd, **Cooke JP**, Winkelman RK: High-dose vitamin A therapy for Darier's disease. *Arch Dermatol*. 1982 Nov;118(11):891-4
3. **Cooke JP**, Shepherd JT, Vanhoutte PM: The effect of warming on adrenergic neurotransmission in canine cutaneous vein. *Circ Res* 1984 May;54(5):547-53
4. Flavahan NA, Rimele TJ, **Cooke JP**, Vanhoutte PM: Characterization of postjunctional alpha-1 and alpha-2 adrenoceptors activated by exogenous or nerve-released norepinephrine in the canine saphenous vein. *J Pharmacol Exp Ther* 1984 Sep;230(3):699-705
5. **Cooke JP**, Rimele TJ, Flavahan NA, Vanhoutte PM: Nimodipine and inhibition of alpha-adrenergic activation of the isolated canine saphenous vein. *J Pharmacol Exp Ther* 1985 Sep;234(3):598-602
6. Flavahan NA, **Cooke JP**, Shepherd JT, Vanhoutte PM: Human postjunctional alpha-1 and alpha-2 adrenoceptors: Differential distribution in arteries of the limbs. *J Pharmacol Exp Ther* 1987 May;241(2):361-5
7. Luscher TF, **Cooke JP**, Houston DS, Neves RJ, Vanhoutte PM: Endothelium-dependent relaxation in human arteries. *Mayo Clin Proc* 1987 Jul;62(7):601-6
8. **Cooke JP**, Shepherd JT, Vanhoutte PM: Vasoconstriction induced by ouabain in the canine coronary artery: Contribution of adrenergic and non-adrenergic responses. *Cardiovasc Drug Ther* 1988
9. Loscalzo J, Smick D, Andon N, **Cooke JP**: S-nitrosocaptopril. I. Molecular characterization and effects on the vasculature and on platelets. *J Pharmacol Exp Ther* 1989 Jun;249(3):726-729

10. **Cooke JP**, Andon N, Loscalzo J: S-nitrosocaptopril. II. Effects on vascular reactivity. *J Pharmacol Exp Ther* 1989 June;249(3):730-4
11. Stamler JS, Mendelsohn ME, Amarante P, Smick D, Andon N, Davies PF, **Cooke JP**, Loscalzo J: N-acetylcysteine potentiates platelet inhibition by endothelium-derived relaxing factor. *Circ Res* 1989 Sep;65(3):789-95
12. Dubin D, Pratt RE, **Cooke JP**, Dzau VJ: Endothelin, a potent vasoconstrictor, is a vascular smooth muscle mitogen. *J Vasc Med Biol* 1989;1:150-154
13. Weidinger FF, McLenachan JM, Cybulsky M, Gordon JM, Rennke HA, Hollenberg NK, Fallon JT, Ganz P, **Cooke JP**: Persistent dysfunction of regenerated endothelium following balloon angioplasty of rabbit iliac artery. *Circulation* 1990 May;81(5):1667-79
14. Creager MA, **Cooke JP**, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, Dzau VJ: Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. *J Clin Invest* 1990 Jul; 86(1):228-34
15. **Cooke JP**, Osmundson PJ, Creager MA, Shepherd JT: Sex differences in control of cutaneous blood flow. *Circulation* 1990 Nov;82(5):1607-15
16. **Cooke JP**, Stamler JS, Andon N, Davies PF, McKinley G, Loscalzo J: Flow stimulates endothelial cells to release a nitrovasodilator that is potentiated by reduced thiol. *Am J Physiol* 1990 Sep;259(3 Pt 2):H804-12
17. Girerd XJ, Hirsch AT, **Cooke JP**, Dzau VJ, Creager MA: L-arginine augments endothelium-dependent vasodilation in cholesterol-fed rabbits. *Circ Res* 1990 Dec;67(6):1301-8
18. **Cooke JP**, Andon NA, Girerd XJ, Hirsch AT, Creager MA: Arginine restores cholinergic relaxation of hypercholesterolemic rabbit thoracic aorta. *Circulation* 1991 Mar;83(3):1057-62
19. Rossitch E, Alexander E III, Black PM, **Cooke JP**: L-arginine normalizes endothelial function in cerebral vessels from hypercholesterolemic rabbits. *J Clin Invest* 1991 Apr;87(4):1295-9
20. Weidinger FS, McLenachan JM, Cybulsky MI, Fallon JT, **Cooke JP**, Ganz P: Hypercholesterolemia enhances macrophage recruitment and endothelial vasodilator dysfunction after balloon injury. *Circulation* 1991 Aug;84(2):755-67
21. **Cooke JP**, Dzau VJ, Creager MA: Endothelial dysfunction in hypercholesterolemia is corrected by L-arginine. *Basic Res Cardiol* 1991;86 Suppl 2: 173-81
22. Shaffer JE, Lee F, Thomson S, Han B-J, **Cooke JP**, Loscalzo J: The hemodynamic effects of S-nitrosocaptopril in anesthetized dogs. *J Pharmacol Exp Ther* 1991 Feb;256(2):704-9
23. **Cooke JP**, Rossitch E, Andon N, Loscalzo J, Dzau VJ: Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator. *J Clin Invest* 1991 Nov;88(5):1663-71

24. Creager MA, Gallagher SJ, Girerd XJ, Coleman S, Dzau VJ, **Cooke JP**: L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. *J Clin Invest* 1992 Oct;90(4):1248-53
25. **Cooke JP**, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME: Anti-atherogenic effects of L-arginine in the hypercholesterolemic rabbit. *J Clin Invest* 1992 Sep;90(3):1168-72
26. **Cooke JP**, Wang B-Y, Andon N, Loscalzo J, Dzau VJ: S-nitrosocaptopril: A novel vasodilator resistant to nitrate tolerance. *J Vasc Med Biol* 1993; 4:115-121
27. Ohno M, Gibbons GH, Dzau VJ, **Cooke JP**: Shear stress elevates endothelial cGMP: Role of a potassium channel and G protein coupling. *Circulation* 1993 Jul;88(1):193-7
28. Candipan RC, Hsiun PT, Pratt R **Cooke JP**: Vascular injury augments adrenergic neurotransmission. *Circulation* 1994 Feb;89(2):777-84
29. Drexler H, Fischell TA, Pinto FJ, Chenzbraun A, **Cooke JP**, Alderman EA: Effect of L-arginine on coronary endothelial function in cardiac transplant recipients: Relationship to vessel wall morphology. *Circulation* 1994Apr;89(4):1615-23
30. Tsao P, McEvoy LM, Drexler H, Butcher EC, **Cooke JP**: Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. *Circulation* 1994 May;89(5):2176-82
31. Tsao PS, Theilmeier G, Singer AH, Leung LL, **Cooke JP**: L-arginine attenuates platelet reactivity in hypercholesterolemic rabbits. *Arterioscler Thromb* 1994 Oct;14(10):1529-33
32. Wang B, Singer A, Tsao P, Drexler H, Kosek J, **Cooke JP**: Dietary arginine prevents atherogenesis in the coronary artery of the hypercholesterolemic rabbit. *J Am Coll Cardiol* 1994 Feb;23(2):452-8
33. Wang BY, Xu CB, **Cooke JP**, Kosek J: An observation of antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. *J Beijing Med Univ* 1994;26:189-191 + p. 11
34. Mann MJ, Gibbons GH, Kernoff RS, Diet FP, Tsao PS, **Cooke JP**, Kaneda Y, Dzau VJ: Genetic engineering of vein grafts resistant to atherosclerosis. *Proc Natl Acad Sci USA* 1995 May9;92(10):4502-6
35. Mason JJ, Owen DK, Harris RA, **Cooke JP**, Hlatky MA: The role of coronary angiography and coronary revascularization before non-cardiac vascular surgery. *JAMA* 1995 Jun28;273(24):1919-25
36. Ohno M, **Cooke JP**, Dzau VJ, Gibbons GH: Fluid shear stress induces endothelial transforming growth factor beta-1 transcription and production via flow-activated potassium channels. *J Clin Invest* 1995 Mar;95(3):1363-9
37. Singer AH, Tsao PS, Wang BY, Bloch DA, **Cooke JP**: Discordant effects of dietary L-arginine on vascular structure and reactivity in the hypercholesterolemic rabbit. *J Cardiovasc Pharmacol* 1995 May;25(5):710-6

38. Smith RL, Donlon BS, Gupta MK, Mohtai M, Das P, Carter DR, **Cooke JP**, Gibbons G, Hutchinson N, Schurman DJ: Effects of fluid-induced shear on articular chondrocyte morphology and metabolism *in vitro*. *J Orthopaedic Res* 1995;13: 824-31
39. Tsao PS, Lewis NP, Alpert S, **Cooke JP**: Exposure to shear stress alters endothelial adhesiveness: Role of nitric oxide. *Circulation* 1995 Dec 15;92(12):3513-9
40. von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, Kaneda Y, **Cooke JP**, Dzau VJ: Gene therapy inhibiting neointimal vascular lesion: *In vivo* transfer of endothelial cell nitric oxide synthase gene. *Proc Natl Acad Sci USA* 1995 Feb 14;92(4):1137-41
41. Walls CM, Gregory CR, Beck LS, **Cooke JP**, Griffey S, Kass PH: Effects of growth factors and L-arginine on ischemic skin flaps in rats. *Vet Surg* 1995 Nov-Dec;24(6):484-91
42. Candipan RC, Wang B, Buitrago R, Tsao PS, **Cooke JP**: Regression or progression: Dependency upon vascular nitric oxide. *Arterioscler Thromb Vasc Biol* 1996 Jan;16(1):44-50
43. Gregory C, **Cooke JP**, Patz JD, Berryman ER, Shorthouse R, Morris RE: Enhanced nitric oxide production induced by the administration of L-arginine does not inhibit arterial neointimal formation after overwhelming alloimmune injury. *J Heart Lung Transplant* 1996 Jan;15(1 Pt 1):58-66
44. Haywood GA, Tsao PS, von der Leyen HE, Mann MJ, Keeling PJ, Trindade PT, Lewis NP, Byrne CD, Rickenbacher PR, Bishopric NH, **Cooke JP**, McKenna WJ, Fowler MB: Expression of inducible nitric oxide synthase in human heart failure. *Circulation* Mar 1996 Mar 15;93(6):1087-94
45. Niebauer J, **Cooke JP**: Cardiovascular effects of exercise: Role of endothelial shear stress. *J Am Coll Cardiol* 1996; 28:1652-1660
46. Lewis NP, Tsao PS, Rickenbacher PR, Xue C, Johns RA, Haywood GA, von der Leyen H, Trindade PT, **Cooke JP**, Hunt SA, Billingham ME, Valantine HA, Fowler MB: Induction of nitric oxide synthase in the human cardiac allograft is associated with contractile dysfunction of the left ventricle. *Circulation* 1996 Feb 15;93(4):720-9
47. Mohtai, M, Gupta MK, Donlon B, Ellison B, **Cooke JP**, Gibbons G, Schurman DJ, Smith RL: Expression of interleukin-6 in osteoarthritic chondrocytes and effects of fluid-induced shear on this expression in normal human chondrocytes *in vitro*. *J Orthopaedic Res* 1996; 14:67-73
48. Tropea BI, Huie P, **Cooke JP**, Tsao PS, Sibley RK, Zarins CK: Hypertension-enhanced monocyte adhesion in experimental atherosclerosis. *J Vasc Surg* 1996 Apr;23(4):596-605
49. Tsao PS, Buitrago R, Chan JR, **Cooke JP**: Fluid flow inhibits endothelial adhesiveness: Nitric oxide and transcriptional regulation of VCAM-1. *Circulation* 1996 Oct 1;94(7):1682-9

50. Wang BY, Candipan RC, Arjomandi M, Hsiun PTC, Tsao PS, **Cooke JP**: Arginine restores NO activity and inhibits monocyte accumulation after vascular injury in hypercholesterolemic rabbits. *J Am Coll Cardiol* 1996 Nov 15;28(6):1573-9
51. Wang BY, Niebauer J, Singer AH, Tsao PS, **Cooke JP**: Felodipine inhibits intimal lesion formation in the hypercholesterolemic rabbit: Differential effects on endothelial and monocyte determinants of atherogenesis. *Vasc Med* 1996;1(3):173-9
52. Carantoni M, Abbasi F, Chu L, Chen YD, Reaven GM, Tsao PS, Varasteh B, **Cooke JP**: Adherence of mononuclear cells to endothelium in vitro is increased in patients with NIDDM. *Diabetes Care* 1997 Sep;20(9):1462-5
53. **Cooke JP**, Creager SJ, Scales KM, Ren C, Tsapatsaris NP, Beetham WP Jr., Creager MA: Role of digital artery adrenoceptors in Raynaud's disease. *Vasc Med* 1997;2(1):1-7
54. Mann MJ, Gibbons GH, Tsao PS, von der Leyen H, **Cooke JP**, Buitrago R, Kernoff R, Dzau VJ: Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. *J Clin Invest* 1997 Mar 15;99(6):1295-301
55. McEvoy LM, Jutila MA, Tsao PS, **Cooke JP**, Butcher EC: Anti-CD43 inhibits monocyte-endothelial adhesion in inflammation and atherogenesis. *Blood* 1997 Nov 1;90(9):3587-94
56. McEvoy LM, Sun H, Tsao PS, **Cooke JP**, Berliner JA, Butcher EC: Novel vascular molecule involved in monocyte adhesion to aortic endothelium in models of atherogenesis. *J Exp Med* 1997 June 16;185(12):2069-77
57. Schwarzacher SP, Lim TT, Wang BY, Kernoff RS, Niebauer J, **Cooke JP**, Yeung AC: Local intramural delivery of L-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty. *Circulation* 1997 Apr 1;95(7):1863-9
58. Theilmeyer G, Chan J, Zalpour C, Anderson B, Wang BY, Wolf A, Tsao PS, **Cooke JP**: Adhesiveness of mononuclear cells in hypercholesterolemic humans is normalized by dietary arginine. *Arterioscler Thromb Vasc Biol* 1997 Dec;17(12):3557-64
59. Tsao PS, Wang B, Buitrago R, Shyy JY, **Cooke JP**: Nitric oxide regulates monocyte chemotactic protein-1. *Circulation* 1997 Aug 5;96(3):934-40
60. Wolf A, Zalpour C, Theilmeyer G, Wang, B-Y, Ma A, Anderson B, Tsao PS, **Cooke JP**: Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. *J Am Coll Cardiol* 1997 Mar 1;29(3):479-85
61. Tsao PS, Niebauer J, Buitrago R, Lin PS, Wang BY, **Cooke JP**, Chen YD, Reaven GM: Interaction of diabetes and hypertension determinants of endothelial adhesiveness. *Arterioscler Thromb Vasc Biol* 1998 Jun;18(6):947-53
62. Boger R, Bode-Boger S, Szuba A, Tsao PS, Chan J, Tangphao O, Blaschke T, **Cooke JP**: Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. *Circulation* 1998 Nov 3;98(18):1842-7

63. Teranishi K, Poston RS, Tsao PS, Asagami T, **Cooke JP**, Reitz BA, Robbins RC: Effect of cyclosporine on chronic graft vascular disease in a rat cardiac isograft model. *Transplant Proc.* 1998 Jun;30(4):1012-3
64. Maxwell AJ, Schauble E, Bernstein D, **Cooke JP**:: Limb Blood Flow during Exercise is Dependent Upon Nitric Oxide. *Circulation* 1998 Jul 28; 98(4):369-74
65. Niebauer J, Maxwell AJ, Lin PS, Tsao PS, Kosek J, Bernstein D, **Cooke JP**: Impaired aerobic capacity in hypercholesterolemic mice: partial reversal by exercise training. *Amer J Physiol*, 1999 Apr;276(4 Pt 2):H1346-H54
66. Wang BY, Ho HK, Lin PS, Schwarzacher SP, Pollman MJ, Gibbons GH, Tsao PS, **Cooke JP**: Regression of atherosclerosis: role of nitric oxide and apoptosis. *Circulation* 1999 Mar 9;99(9):1236-41
67. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, **Cooke JP**. Novel Mechanism for Endothelial Dysfunction : Dysregulation of Dimethylarginine Dimethylaminohydrolase *Circulation* 1999 Jun 22;99(24): 3092-5
68. Miyazaki H, Matsuoka H, **Cooke JP**, Usui M, Ueda S, Okuda S, Imaizumi T. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. *Circulation* 1999 Mar 9;99(9):1141-6
69. **Cooke JP**, Bhatnagar R, Szuba A, Rockson SG: Fibroblast growth factor as therapy for critical limb ischemia: a case report. *Vasc Med* 1999;4(2): 89-91
70. Niebauer J, Dulak J, Chan JR, Tsao PS, **Cooke JP**: Gene Transfer of nitric oxide synthase; effects on endothelial biology. *J Am Coll Cardiol* 1999 Oct; 34 (4):1201-07
71. Hutchison SJ, Sudhir K, Sievers RE, Zhu BQ, Sun YP, Chou TM, Chatterjee K, Deedwania PC, **Cooke JP**, Glantz SA, Parmley WW: Effects of L-arginine on atherogenesis and endothelial dysfunction due to secondhand smoke. *Hypertension* 1999 Jul;34(1):44-50
72. Tangphao O, Chalon S, Coulston AM, Moreno H Jr, Chan JR, **Cooke JP**, Hoffman BB, Blaschke TF: L-arginine and nitric oxide-related compounds in plasma: comparison of normal and arginine-free diets in a 24-h crossover study. *Vasc Med* 1999;4(1):27-32
73. Niebauer J, Schwarzacher SP, Hayase M, Wang B, Kernoff RS, **Cooke JP**, Yeung AC: Local L-arginine delivery after balloon angioplasty reduces monocyte binding and induces apoptosis. *Circulation* 1999 Oct 26;100(17): 2830-5
74. Dulak J, Jozkowicz A, Dembinska-Kiec A, Guevara I, Zdzienicka A, Zmudzinska-Grochot D, Florek I, Wojtowicz A, Szuba A, **Cooke JP**: Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol* 2000 Mar;20(3):659-66
75. Maxwell A, Anderson B, **Cooke JP**: Endothelial dysfunction in hypercholesterolemia is reversed by a nutritional product designed to enhance nitric oxide activity. *Cardiovasc Drugs Ther* 2000 Jun;14(3): 309-16

76. Maxwell A, Anderson B, **Cooke JP**: Nutritional therapy for peripheral arterial disease: A double blind, placebo-controlled randomized trial of HeartBar. *Vasc Med* 2000;5(1):11-20
77. Boger RH, Bode-Boger SM, Tsao PS, Lin PS, Chan JR, **Cooke JP**: An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. *J Am Coll Cardiol* 2000 Dec;36(7):2287-95
78. Chan JR, Boger RH, Bode-Boger SM, Tangphao O, Tsao P, Blaschke TF, **Cooke JP**: Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. *Arterioscler Thromb Vasc Biol* 2000 Apr;20(4):1040-6
79. Romero LI, Zhang DN, **Cooke JP**, Ho HK, Avalos E, Herrera R, Herron GS: Differential regulation (expression) of nitric oxide by dermal microvascular endothelial cells from patients with scleroderma. *Vasc Med* 2000 5(3):147-58
80. Lissin L, **Cooke JP**: Phytoestrogens and their effects on the cardiovascular system. *J Am Coll Cardiol* 2000; May;35(6):1403-10
81. Jang J, Ho H-K, Kwan HH, Adimoolam S, Fajardo LF, **Cooke JP**: Angiogenesis is impaired by hypercholesterolemia: role of asymmetric dimethylarginine. *Circulation* 2000 Sep 19;102(12):1414-9
82. Uemura S, Fathman G, Rothbard J, **Cooke JP**: Rapid and efficient vascular transport of arginine polymers inhibits myointimal hyperplasia. *Circulation* 2000 Nov 21;102(21):2629-35
83. Dulak J, Jozkowicz A, Ratajska A, Szuba A, **Cooke JP**, Dembinska-Kiec A: Vascular endothelial growth factor is efficiently synthesized in spite of low transfection efficiency of pSG5VEGF plasmids in vascular smooth muscle cells. *Vasc Med* 2000;5(1):33-40
84. Szuba A, **Cooke JP**, Yousuf S, Rockson SG: Decongestive lymphatic therapy for patients with cancer-related or primary lymphedema. *Am J Med* 2000 Sep 1;109(4): 296-300
85. Rockson SG, Kramer P, Razavi M, Szuba A, Filardo S, Fitzgerald P, **Cooke JP**, Yousuf S, DeVault AR, Renschler MF, Adelman DC: Photoangioplasty for human peripheral atherosclerosis: results of a phase I trial of photodynamic therapy with motexafin lutetium. *Circulation* 2000 Nov 7;102(19):2322-4
86. Maxwell AJ, Ho HV, Le CQ, Lin PS, Bernstein D, **Cooke JP**: L-arginine enhances aerobic exercise capacity in association with augmented nitric oxide production. *J Appl Physiol* 2001 Mar;90(3):933-8
87. Lundman P, Eriksson MJ, Stuhlinger M, **Cooke JP**, Hamsten H, Tornvall P: Mild to moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. *J Am Coll Cardiol* 2001 Jul;38(1):111-6

88. Jozkowicz A, **Cooke JP**, Guevara I, Huk I, Funovics P, Pachinger O, Weidinger F, Dulak J: Genetic augmentation of nitric oxide synthase increases the vascular generation of VEGF. *Cardiovasc Res* 2001 Sep;51(4):773-83
89. Hiatt WR, Regensteiner JG, Creager MA, Hirsch AT, **Cooke JP**, Olin JW, Gorbunov GN, Isner J, Lukjanov YV, Tsitsiashvili MS, Zabelskaya TF, Amato A: Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. *Am J Med* 2001 Jun 1;110(8):616-22
90. Heeschen C, Jang J, Hoai-Ky V, Kaji S, Yang P, Hu RS, **Cooke JP**: Nicotine is an agent of angiogenesis. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. *Nat Med* 2001 Jul; 7(7):833-9
91. Matsushita H, Chang E, Glassford AJ, **Cooke JP**, Chiu CP, Tsao PS: eNOS activity is reduced in senescent human endothelial cells: Preservation by hTERT immortalization. *Circ Res* 2001 Oct 26; 89(9): 793-8
92. Affasi F, Asagmi T, **Cooke JP**, Lamendola C, McLaughlin T, Reaven GM, Stuehlinger M, Tsao PS: Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. *Am J Cardiol* 2001 Nov 15; 88(10):1201-3
93. Stuhlinger MC, Tsao PS, Her J-H, Kimoto M, Balint RF, **Cooke JP**: Homocysteine impairs the NO synthase pathway - Role of asymmetric dimethylarginine. *Circulation* 2001 Nov 20; 104(21):2569-75
94. Niebauer J, Tsao PS, Lin PS, Pratt RE, **Cooke JP**: Cholesterol-induced upregulation of angiotensin II and its effects on monocyte-endothelial interaction and superoxide production. *Vasc Med*. 2001;6(3):133-8
95. Schwarzacher SP, Tsao PS, Ward M, Hayase M, Niebauer J, **Cooke JP** and Yeung AC: Effects of stenting on adjacent vascular distensibility and neointima formation: role of nitric oxide. *Vasc Med* 6(3): 139-144
96. Cooper LT, Hiatt WR, Creager MA, Regensteiner JG, Casscells W, Isner JM, **Cooke JP**, Hirsch AT: Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication. *Vasc Med* 2001; 6(4): 235-239
97. Weis M, Heeschen C, **Cooke JP**: HMG-CoA reductase inhibition has biphasic effects on angiogenesis. *Circulation* 2002 Feb 12;105(6):739-45.
98. Suzuki T, Hayase M, Hibi K, Hosokawa H, Yokoya K, Fitzgerald PJ, Yock PG, **Cooke JP**, Suzuki T, Yeung AC: Effect of local delivery of L-arginine on in-stent restenosis in humans. *Am J Cardiol*. 2002 Feb 15;89(4):363-367
99. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, **Cooke JP**, Reaven GM, Tsao PS Relationship Between Insulin Resistance and an Endogenous Nitric Oxide Synthase Inhibitor . *Journal of the American Medical Association* 2002; 287(11): 1420-1426
100. Jacobi J, Jang JJ, Sundram U, Fajardo L, **Cooke JP**: Nicotine stimulates wound healing in diabetic mice. *Am J Pathol* 2002 Jul;161(1):97-104

101. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, Tsuji H, Reaven G, **Cooke JP**: Impaired nitric oxide synthase pathway in diabetes mellitus: Role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. *Circulation* 2002 Aug 20;106(8):987-92
102. Asagami T, Abbasi F, Stuehlinger M, Lamendola C, McLaughlin T, **Cooke JP**, Reaven GM, Tsao PS: Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. *Metabolism* 2002 Jul;51(7):843-6.
103. Heeschen C, Weis M, **Cooke JP**: A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. *J Clin Invest* 2002 Aug;110(4):527-36
104. Tawakol A, Forgione MA, Stuehlinger M, Alpert NM, **Cooke JP**, Loscalzo J, Fischman AJ, Creager MA and Gewirtz H: Homocysteine impairs coronary microvascular dilator function in humans. *J Am Coll Cardiol* 2002; 40(6): 1051-1058
105. Weis M, Schlichting CL, Engleman EG, **Cooke JP**: Endothelial determinants of dendritic cell adhesion and migration. *Arterioscl Thromb Vasc Biol* 2002 Nov 1;22(11):1817-23.
106. Heeschen C, Weis M, **Cooke JP**: Nicotine promotes arteriogenesis. *J Am Coll Cardiol*, 2003 Feb 5;41(3):489-96
107. Uemura S, Rothbard J, Matsushita H, Tsao PS, Fathman CG, **Cooke JP**: Short polymers of arginine rapidly translocate into vascular cells: Effects on nitric oxide synthesis. *Circulation Journal Circ J* 2002 Dec;66(12):1155-60
108. Aicher A, Heeschen C, Mohaupt M, **Cooke JP**, Zeiher AM, and Dimmeler S: Nicotine Strongly Activates Dendritic Cell-Mediated Adaptive Immunity – Potential Role for Progression of Atherosclerotic Lesions. *Circulation*. 2003 Feb 4;107(4):604-11.
109. Niebauer J, Maxwell, AJ, Lin PS, Heidari S, Tsao P, **Cooke JP**: NOS inhibition accelerates atherogenesis: Reversal by exercise. *Am J Physiol Heart Circ Physiol*. 2003 Feb 21 [epub ahead of print]
110. Stuhlinger MC, Oka RK, Graf EE, Schmolzer I, Upson BM, Kapoor O, Szuba A, Malinow MR, Wascher TC, Pachinger O and **Cooke JP**: Endothelial dysfunction induced by hyperhomocysteinemia: Role of ADMA *Circulation* 2003 Aug 26;108(8):933-8.
111. Ward MR, Tsao PS, Herity NA, **Cooke JP**, Yeung AC: Flow-responsive remodeling after angioplasty is enhanced by high cholesterol diet. Prevention with pyrrolidine dithiocarbamate. *Atherosclerosis*. 2003 Jun;168(2):333-41.
112. Scuteri A, Stuehlinger MC, **Cooke JP**, Wright JG, Lakatta EG, Anderson DE, Fleg JL. Nitric oxide inhibition as a mechanism for blood pressure increase during salt loading in normotensive postmenopausal women. *J Hypertens*. 2003 Jul;21(7):1339-1346.
113. Engler MM, Engler MB, Malloy MJ, Chiu EY, Schloetter, Stuehlinger M, Lin KY, **Cooke JP**, Morrow JD, Ridker PM, Rifai N, Mietus-Snyder M: Antioxidant Vitamins C and E Improve Endothelial Function in Children and Adolescents with Hyperlipidemia:

- Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. *Circulation* 2003 Sep 2;108(9):1059-63.
114. Oka RK, Szuba A, Giacomini JC, Kapoor O, Bene G, Soltani A, and **Cooke JP**: Gender differences in the perception of PAD: a pilot study. *Vascular Medicine* 2003 8(2):89-94.
 115. Zhu B, Heeschen C, Sievers RE, Karliner JS, Parmley WW, Glantz SA and **Cooke JP**: Second Hand Smoke Stimulates Tumor Angiogenesis and Growth, *Cancer Cell* 2003; 4(3):191-6
 116. Dayoub H, Achan V, Adimoolam S, Jacobi J, Stuehlinger M, Wang B, Tsao PS, Kimoto M, Vallance P, Patterson AJ, **Cooke JP**: DDAH Regulates NO Synthesis: Genetic and physiological evidence. *Circulation* 2003; 108: 1043-1048
 117. Oka RK, Szuba A, Giacomini JC, and **Cooke JP**: Predictors of physical function in patients with peripheral arterial disease and claudication. *Progress in Cardiovascular Nursing* 2004; 19(3):89-94.
 118. Weis M, Kledal TN, Lin KY, Panchal SN, Gao SZ, Valantine HA, Mocarski ES, **Cooke JP**: Cytomegalovirus infection impairs the NOS pathway. Role of ADMA in transplant arteriosclerosis. *Circulation* 2004 Feb 3;109(4):500-5.
 119. Fearon WF, Aarnoudse W, Pijls NH, De Bruyne B, Balsam LB, **Cooke DT**, Robbins RC, Fitzgerald PJ, Yeung AC, Yock PG. Microvascular resistance is not influenced by epicardial coronary artery stenosis severity: experimental validation. *Circulation* 2004; 109(19):2269-2272.
 120. Lissin LW, Oka R, Lakshmi S, **Cooke JP**: Isoflavones improve vascular reactivity in post-menopausal women with hypercholesterolemia. *Vasc Med* 2004; 9(1):26-30, 2004
 121. Hiatt WR, Hirsch AT, **Cooke JP**, Olin JW, Brater DC, Creager MA: Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy. *Vascular Medicine* 9(1): 26-30, 2004
 122. Jacobi J, Tam BYY, Sundram U, von Degenfeld G, Blau HM, Kuo CJ, **Cooke JP**: Discordant effects of a soluble VEGF receptor on wound healing and angiogenesis. *Gene Therapy* 2004 11(3):302-9.
 123. Ho H-K V, Jang JJ, Kaji S, Spektor G, Fong A, Yang P, Hu RS, Schatzman R, Quertermous T, **Cooke JP**: Developmental Endothelial Locus-1 (Del-1): a Novel Angiogenic Protein. Its Role in Ischemia *Circulation*. 2004 Mar 16;109(10):1314-9. Epub 2004 Feb 23.
 124. Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, **Cooke JP**, Böger RH: Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. *Clin Chem Lab Med* 2004; 42(12): 1377-83
 125. Jacobi J, Tam BYY, Wu G, Hoffman J, **Cooke JP** and Kuo CJ: Adenoviral gene transfer with soluble VEGF receptors impairs angiogenesis and perfusion in a murine model of hindlimb ischemia *Circulation*. 2004 Oct 19;110(16):2424-9. Epub 2004 Oct 11.

126. Trapp G, Sydow K, Dulay MT, Chou T, **Cooke JP**, Zare RN: Capillary Electrophoretic and Micellar Electrokinetic Separations of Asymmetric Dimethyl-L-Arginine and Structurally Related Amino Acids: Quantitation in Human Plasma. *J. Sep. Sci.* 2004 Dec;27(17-18):1483-90.
127. Jacobi J, Sydow K, von Degenfeld G, Zhang Y, Dayoub H, Wang B, Patterson AJ, Kimoto M, Blau HM, **Cooke JP**: Overexpression of Dimethylarginine Dimethylaminohydrolase (DDAH) Reduces Tissue ADMA Levels and Enhances Angiogenesis. *Circulation* 2005 Mar 22;111(11):1431-8.
128. Achan V, Ho HK, Heeschen C, Stuehlinger M, Jang JJ, Kimoto M, Vallance P, **Cooke JP**: ADMA regulates angiogenesis: genetic and metabolic evidence. *Vascular Medicine* 2005 Feb;10(1):7-14.
129. Oka, RK Umoh E, Szuba A, Giacomini JC and **Cooke JP**. Suboptimal Intensity of risk factor modification in PAD. *Vascular Medicine* (2005) 10:91-96.
130. Tanaka M, Sydow K, Gunawan F, Jacobi J, Tsao PS, Robbins RC and **Cooke JP**: DDAH overexpression suppresses graft coronary artery disease in murine cardiac allografts. *Circulation* 2005 Sep 13;112(11):1549-56. Epub 2005 Sep 6.
131. Oka RK, Altman M, Giacomini JC, Szuba A, **Cooke JP**: Abnormal cardiovascular response to exercise in patients with peripheral arterial disease: Implications for management. *J Vasc Nurs.* 2005 Dec;23(4):130-6.
132. Qureshi I, Chen H, Brown AT, Fitzgerald R, Wang Y, Breckenridge J, Kazi R, Crocker AJ, Stühlinger MC, Lin K, **Cooke JP**, Moursi MM: Homocysteine-induced vascular dysregulation is mediated by the NMDA Receptor. *Vascular Medicine* 10(3): 215-223, 2005
133. Oka RK, Szuba A, Giacomini JC, **Cooke JP**: A Pilot Study of L-arginine supplementation on functional capacity in peripheral arterial disease *Vascular Medicine* 2005 Nov;10(4):265-74.)
134. Nair N, Oka RK, Waring LD, Umoh EM, Barr Taylor MD, **Cooke JP**: Vascular compliance versus flow-mediated vasodilation: Correlation with cardiovascular risk factors *Vascular Medicine*, 2005 Nov;10(4):275-83
135. Kielstein JT, Donnerstag F, Gasper S, Menne J, Kielstein A, Martens-Lobenhoffer J, Scalera F, **Cooke JP**, Fliser D, Bode-Böger SM: ADMA increases arterial stiffness and decreases cerebral blood flow in man. *Stroke* 2006; 37: 2024-9
136. Kielstein J.T., Salpeter S.R.; Bode-Böger S.M., **Cooke J.P.**, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function – a meta-analysis. *Nephrol. Dial. Transplant* (2006) **21**: 2446 - 2451
137. Szuba A, Oka RK, Harada R and **Cooke JP**: Limb hemodynamics are not predictive of functional capacity in patients with PAD *Vascular Medicine* 11(3): 155-63, 2006

138. Taylor CB, Conrad A, Wilhelm FH, Neri E, DeLorenzo A, Kramer MA, Giese-Davis J, Roth WT, Oka R, **Cooke JP**, Kraemer H, Spiegel D: Psychophysiological and cortisol responses to psychological stress in depressed and nondepressed older men and women with elevated CVD risk. *Psychosomatic Medicine*, 2006 Jul-Aug;68(4):538-46.
139. Potena L, Holweg C, Chin C, Luikart H, Weisshaar D, Narasimhan B, Fearon WF, Lewis DB, **Cooke JP**, Mocarski ES, Valantine HA: Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. *Transplantation* 2006; 82:398-405
140. Tu W, Potena L, Stepick-Biek P, Liu L, Dionis KY, Luikart H, Fearon WF, Holmes TH, **Cooke JP**, Valantine HA, Mocarski ES and Lewis DB: T-Cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. *Circulation* 2006;114:1608-1615.
141. von Degenfeld G, Banfi A, Springer ML, Jacobi J, Ozawa CR, Merchant MJ, **Cooke JP** and Blau HM: Microenvironmental concentration of VEGF is critical to functional and stable vessel growth in ischemia. *FASEB J*. 2006 Dec;20(14):2657-9.
142. **Cooke JP**, Ma A, Smith WB, Garland T, Anderson B, Messina T, Navarro MT, Skettino S: A double-blind, placebo-controlled pilot trial of ranolazine in the treatment of intermittent claudication. *International Angiology*, 2006, 25(4): 361-9
143. Heeschen C, Chang E, Aicher A, Dimmeler S, **Cooke JP**: Endothelial progenitor cells participate in nicotine-mediated angiogenesis. *J Am Coll Cardiol*. 2006 Dec 19;48(12):2553-60
144. Ng M, Wu J, Chang E, Wang B-Y, Katzenburg-Clark R, Ishii-Watabe A, Gerritsen ME, **Cooke JP**: A central role for nicotinic cholinergic regulation of growth factor-induced endothelial cell migration – Novel insights into angiogenesis. *Arterioscler Thromb Vasc Biol*. 2007 Jan;27(1):106-12.
145. Aicher A, Johnson FL, Fandrich F, Siebert R, Dimmeler S, **Cooke JP**, Heeschen C: Non-bone marrow-derived circulating cells contribute to postnatal neovascularization following tissue ischemia. *Circulation Research* 2007; Mar 2;100(4):581-9.
146. Iribarren C, Husson G, Sydow K, Wang BY, Sidney S, **Cooke JP**: Asymmetric Dimethyl-Arginine (ADMA) and Coronary Artery Calcification in Young Adults Entering Middle Life: the CARDIA Study. *European Journal of Cardiovascular Prevention and Rehabilitation* 2007 Apr;14(2):222-9.
147. Konishi H, Wu J, Sydow K, **Cooke JP**: Dimethylarginine dimethylaminohydrolase (DDAH) promotes endothelial repair after vascular injury. *J Am Coll Cardiol*. 2007 Mar 13;49(10):1099-105.
148. Peter C, Kielstein JT, Clarke-Katzenberg R, Adams MC, Pitsiouni M, Kambham N, Kengatharan KM and **Cooke JP**: A novel bioluminescent tumor model of human renal cancer cell lines: an in vitro and in vivo characterization. *J Urology* 2007 Jun;177(6):2342-6.

149. Fearon WF, Potena L, Hirohata A, Luikart H, Vana ML, **Cooke JP**, Mocarski EM, Yeung AC and Valentine HA: Changes in Coronary Arterial Dimensions Early after Cardiac Transplantation. *Transplantation* 2007 (83):700-5
150. Xu L, Wang B, Kaur K, Kho MF, Cooke JP and Giffard RG: Alterations in NO and ADMA with acute cerebral ischemia, amelioration with the chaperonin GroEl. *Neuroscience Letters* 2007 May 17;418(2):201-4.
151. Wilson A, Harada R, Nair N, Balasubramanian N, Cooke JP: L-arginine supplementation in peripheral arterial disease: No benefit and possible harm. *Circulation* 2007 Jul 10;116(2):188-95.
152. Potena L, Holweg CTJ, Vana ML, Bashyam L, Rajamani J, McCormick AL, **Cooke JP**, Valentine HA, and Mocarski ES: Frequent occult infection with cytomegalovirus despite antiviral prophylaxis in cardiac transplant recipients *J Clin Microbiol* 2007 Jun;45(6):1804-10.
153. Stuhlinger MC, Conci E, Haubner BJ, Stocker EM, Schwaighofer J, **Cooke JP**, Tsao PS, Pachinger O and Metzler B: Asymmetric dimethyl L-arginine (ADMA) is a critical regulator of myocardial reperfusion injury. *Cardiovascular Research* 2007 Jul 15;75(2):417-425.
154. Li Z, Wu JC, Sheikh AY, Kraft D, Cao F-, Xie X, Robbins RC, **Cooke JP**, Wu JC: Differentiation, survival, and function of embryonic stem cell-derived endothelial cells for ischemic heart disease. *Circulation* 2007 Sep 11;116(11 Suppl):I46-54.
155. Wilson AM, Kimura E, Harada RK, Nair N, Narasimhan B, Meng X-Y, Zhang F, Beck KR, Olin JW, Fung ET, **Cooke JP**: Beta-2 microglobulin as a biomarker in peripheral arterial disease. Proteomic profiling and clinical studies. *Circulation*. 2007 Sep 18;116(12):1396-403
156. Dayoub H, Rodionov R, Lynch C, **Cooke JP**, Arning E, Bottiglierie T, Lentz SR, Faraci FM: Overexpression of Dimethylarginine Dimethylaminohydrolase Inhibits ADMA-Induced Endothelial Dysfunction in Cerebral Circulation. *Stroke* 2008 39;180-184
157. Potena L, Fearon WF, Sydow K, Holweg C, Luikart H, Chin C, Weisshaar D, Mocarski ES, Lewis DB, Valentine HA, **Cooke JP**: Asymmetric dimethylarginine predicts cardiac allograft vasculopathy progression: modulation by sirolimus. *Transplantation* 2008 Mar 27;85(6):827-833
158. Sydow K, Mondon CE, Schrader J, Konishi H and **Cooke JP**: Dimethylarginine dimethylaminohydrolase enhances insulin sensitivity. *Arterioscler Thromb Vasc Biol*. 2008 Apr;28(4):692-7 [PMID # 18239148. NIHMS125983, Publ.ID: ATV162073]
159. Kiuchi K, Matsuoka M, Wu JC, Lima e Silva R, Kengatharan M, Verghese M, Ueno S, Yokoi K, Khu NH, **Cooke JP** and Campochiaro PA: Mecamylamine suppresses basal and nicotine-stimulated choroidal neovascularization. *Investigative Ophthalmology and Visual Sciences*, 2008 Apr;49(4):1705-11. [PMID # 18385094]
160. Dayal S, Rodionov R, Arning E, Bottiglieri T, Kimoto M, Murry D, **Cooke JP**, Faraci F, Lentz SR: Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase

- in hyperhomocysteinemia *Am J Physiol Heart Circ Physiol*. 2008 Aug;295(2):H816-25. [Epub ahead of print; PMID: 18567702]
161. Fung ET, Wilson AM, Zhang F, Harris N, Edwards KA, Olin JW, **Cooke JP**: A biomarker panel for peripheral arterial disease. *Vascular Medicine*, 2008 Aug;13(3):217-24.
 162. Kielstein JT, Salpeter SR, Buckley NS, **Cooke JP** and Fliser D: Two cardiovascular risk factors in one? Homocysteine and its relation to glomerular filtration rate. A meta-analysis of 41 studies with 27,000 participants. *Kidney & Blood Pressure Research*, 2008; 31:259-26
 163. de Jesus Perez VA, Alastalo TP, Wu JC, Axelrod JD, **Cooke JP**, Amieva M, Rabinovitch M. Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt-beta-catenin and Wnt-RhoA-Rac1 pathways. *J Cell Biol*. 2009 Jan 12;184(1):83-99.
 164. Niiyama H, Huang NF, Rollins M, **Cooke JP**. Murine Model of Hindlimb Ischemia. *J Vis Exp*. 2009 Jan 21;(23). pii: 1035. doi: 10.3791/1035. PMID: 19229179
 165. Huang NF, Niiyama H, De A, Gambhir SS, **Cooke JP**. Embryonic stem cell-derived endothelial cells for treatment of hindlimb ischemia. *J Vis Exp*. 2009 Jan 23;(23). pii: 1034. doi: 10.3791/1034. PMID: 19229180
 166. Taylor CB, Conrad A, Wilhelm FH, Strachowski D, Khaylis A, Neri E, Giese-Davis J, Roth WT, **Cooke JP**, Kraemer H, Spiegel D: Does improving mood in depressed patients alter factors that may affect cardiovascular disease risk? *J Psychiatr Res*. 2009 Jul 3. [Epub ahead of print] PMID: 19577757
 167. Wu JC, Chruscinski A, de Jesus Perez VA, Singh H, Pitsiouni M, Rabinovitch M, Utz PJ, **Cooke JP** : Cholinergic modulation of angiogenesis : Role of the $\alpha 7$ nicotinic acetylcholine receptor. *J Cell Biochem* 2009, Oct 1;108(2):433-46.
 168. Schwedhelm E, von Leitner EC, Atzler D, Schmitz C, Jacobi J, Meinertz T, Münzel T, Baldus S, **Cooke JP**, Böger RH, Maas R, Sydow K. Extensive characterization of the human DDAH1 transgenic mice. *Pharmacol Res*. 2009 Aug 7. [Epub ahead of print] PMID: 19666120
 169. Maxwell AJ, Niebauer J, Lin PS, Tsao PS, Bernstein D, **Cooke JP**: Hypercholesterolemia impairs aerobic exercise capacity in mice *Vasc Med*. 2009 Aug;14(3):249-57. PMID: 19651675
 170. Yang W, Patel K, Ghebremariam Y, Lee J, Wong H-C, **Cooke JP** and Swartz J: Cell-free production of transducible transcription factors for nuclear reprogramming. *Biotechnol Bioeng*. 2009 Aug 28. PMID: 19753305
 171. Yu J, Huang NF, Wilson KD, Velotta JB, Huang M, Li Z, Lee A, Robbins RC, **Cooke JP**, Wu JC: nAChRs Mediate Human Embryonic Stem Cell-Derived Endothelial Cells: Proliferation, Apoptosis, and Angiogenesis. *PLOS One*. 2009 Sep 15;4(9):e7040. PMID: 19718703
 172. Rodionov RN, Dayoub H, Lynch C, Wilson KM, Stevens JW, Murry DJ, Kimoto M, Arning E, Bottiglieri T, **Cooke JP**, Baumbach GL, Faraci FM, Lentz SR: Overexpression of

- Dimethylarginine Dimethylaminohydrolase Protects against Cerebral Vascular Effects of Hyperhomocysteinemia. *Circ Res.* 2009 Dec 17. [Epub ahead of print] PMID: 20019334
173. Huang NF, Fleissner F, Sun J, **Cooke JP**: Role of nitric oxide signaling in endothelial differentiation of embryonic stem cells. *Stem Cells and Development*, epubl 1-11-10.
 174. Konishi H, Wu J, **Cooke JP**: Chronic exposure to nicotine impairs cholinergic angiogenesis. *Vascular Medicine*, 2010 Feb;15(1):47-54.PMID: 19778953
 175. Huang NF, Niiyama H, Peter C, De A, Natkunam Y, Fleissner F, Li Z, Rollins MD, Wu JC, Gambhir SS, **Cooke JP**: Embryonic stem cell-derived endothelial cells incorporate into ischemic hindlimb and restore perfusion. *Arteriosclerosis, Thrombosis and Vascular Biology* 2010 May;30(5):984-91
 176. Campochiaro PA, Shah SM, Hafiz G, Heier JS, Lit ES, Zimmer-Galler I, Channa R, Nguyen QD, Syed B, Do DV, Lu L, Monk J, **Cooke JP**, Kengatharan K, Hsu H: Topical mecamylamine for diabetic macular edema. *Am J Ophthalmol.* 2010 May;149(5):839-51.e1.
 177. Perna M, Roman MJ, Alpert DR, Crow MK, Lockshin MD, Sammaritano L, Devereux RB, **Cooke JP**, Salmon JE. Relationship of asymmetric dimethylarginine and homocysteine to vascular aging in SLE patients. *Arthritis Rheum.* 2010 June; 62(6):pp 1718–1722.
 178. Wilson AM, Shin DS, Weatherby C, Harada RK, Ng MK, Nair N, Kielstein J and **Cooke JP**: Asymmetric dimethylarginine predicts adverse cardiovascular events and mortality in peripheral arterial disease *Vasc Med.* 2010 Aug;15(4):267-74.
 179. Huang NF, Patlolla B, Abilez O, Sharma H, Rajdas J, Beygui RE, Zarins CK, **Cooke JP**: A matrix micropatterning platform for cell localization and stem cell fate determination. *Acta Biomaterialia* 2010 Dec;6(12):4614-21
 180. Chang E, Forsberg C, Wang B, Wu J, Prohaska S, Allsopp R, Weissman IL, **Cooke JP**: Cholinergic activation of hematopoiesis: A new paradigm for tobacco-induced leukocytosis? *Vascular Medicine* 2010 Oct;15(5):375-85.
 181. Rafie AHS, Stefanick ML, Sims ST, Phan T, Higgins M, Gabriel A, Assimes T, Balasubramanian N, Myers J, Olin J, **Cooke JP**: Sex differences in the prevalence of peripheral arterial disease in patients undergoing cardiac catheterization. *Vascular Medicine* 15 (6): 443-50, 2010
 182. Beisswenger P, Ceriello A, **Cooke JP**, Goldberg R, Brown WV, Le N-A, Robbins DC, Sarwat S, Yuan H, Jones CA, Tan MH: Effect of Basal plus Prandial Versus Basal Insulin Therapy on Postprandial Vascular Biomarkers after a High Fat Breakfast in Type 2 Diabetes patients on metformin. *Diabet Med.* 2011 Apr 25.
 183. Wilson AM, Rafie AHS, Myers J, Assimes T, Nead KT, Higgins M, Gabriel A, Olin J, **Cooke JP**: Low lifetime recreational activity is a risk factor for peripheral arterial disease. *J Vasc Surg.* 2011 Jun 8. [Epub ahead of print]

184. Holweg CTJ, Potena L, Luikart H, Yu T, Berry GJ, **Cooke JP**, Valantine HA, Mocarski ES: Identification and classification of acute cardiac rejection by intragraft transcriptional profiling. *Circulation*. 2011 May 24;123(20):2236-43.
185. Yang WC, Welsh JP, Lee J, **Cooke JP** and Swartz J: Solubility partner IF2 domain I enables high yield synthesis of transducible transcription factors in E. coli. *Protein Expr Purif*. 2011 Jul 2. [Epub ahead of print]
186. Razny U, Kiec-Wilk B, Wator L, Polus A, Dyduch G, Solnica B, Malecki M, Tomaszewska R, **Cooke JP**, Dembinska-Kiec A. Increased nitric oxide availability attenuates high fat diet metabolic alterations and gene expression associated with insulin resistance. *Cardiovasc Diabetol*. 2011 Jul 22;10(1):68. [Epub ahead of print]
187. Rufaihah AJ, Huang NF, Jame S, Lee J, Nguyen HN, Byers B, De A, Okogbaa JN, Rollins M, Reijo-Pera R, Gambhir SS, **Cooke JP**: Endothelial cells derived from human iPSCs increase capillary density and improve perfusion in a mouse model of peripheral arterial disease. *Arteriosclerosis, Thrombosis and Vascular Biology*, 2011 Nov;31(11):e72-9 PMID:21836062
188. Tian X, Wong WT, Leung FP, Zhang Y, Wang YX, Lee HK, Ng CF, Chen ZY, Yao X, Au CL, Lau CW, Vanhoutte PM, **Cooke JP**, Huang Y. Oxidative Stress-dependent Cyclooxygenase-2-derived Prostaglandin F2 α Impairs Endothelial Function in Renovascular Hypertensive Rats. *Antioxid Redox Signal*. 2012 Feb 15;16(4):363-73 PMID:21951274
189. Murabito JM...**Cooke JP**...Kronenberg F [124 authors]: Association between chromosome 9p21 variants and the Ankle-brachial Index identified by a meta-analysis of 21 genome-wide association studies. *Circ Cardiovasc Genet*. 2011 Dec 23. [Epub ahead of print]
190. Wassel CL, Murabito JM**Cooke JP**...et al [124 authors]: Genetic Determinants of the Ankle-Brachial Index: A Meta-analysis of a Cardiovascular Candidate Gene 50K SNP Panel in the Candidate Gene Association Resource (CARE) Consortium Atherosclerosis, *Atherosclerosis* 2012 Feb 2. [Epub ahead of print]
191. Ghebremariam YT, Erlanson D, Yamada K and **Cooke JP**: Development of a dimethylarginine dimethylaminohydrolase (DDAH) assay for high throughput chemical screening. *Journal of Biomolecular Screening* 17 (5): 651 – 661 June 2012.
192. Dake M, Dantzker N and **Cooke JP**: Endovascular correction of cerebrovenous anomalies in Multiple Sclerosis: a retrospective review of an uncontrolled case series. *Vasc Med*. 2012 Apr 10. [Epub ahead of print]
193. Hong G, Lee JC, Robinson JT, Raaz U, Xie L, Huang NF, **Cooke JP** and Dai H: Multi-functional in vivo vascular imaging using near-infrared II fluorescence. *Nat Med*. 2012 Dec 6;18(12):1841-6.
194. Lai ES, Huang NF, **Cooke JP** and Fuller GG: Aligned Nanofibrillar Collagen Regulates Endothelial Organization and Migration. *Regenerative Medicine*, 7(5), 649–661(2012)

195. Lee J, Sayed N, Hunter A, Au KF, Wong WH, Mocarski E, Reijo Pera R, **Cooke JP**: Activation of innate immunity is required for efficient nuclear reprogramming. *Cell*. 2012 Oct 26;151(3):547-58.
196. White MP, Rufaihah AJ, Liu L, Ivey KN, **Cooke JP**, and Srivastava D. Limited Gene Expression Variation in Human Embryonic Stem Cell and Induced Pluripotent Stem Cell Derived Endothelial Cells *Stem Cells*, 2013 Jan;31(1):92-103
197. Tian XY, Wong WT, Wang N, Lu Y, Cheang WS, Liu Y, Lee SS, Chen Z-Y, Yao X, **Cooke JP**, Huang Y: PPAR δ activation protects endothelial function in diabetic mice. *Diabetes*. 2012 Dec;61(12):3285-93
198. Huang NF, Okogbaa J, Lee J, Zaitseva T, Paukshto MV, Sun J, Punjya N, Fuller GG and **Cooke JP**: The Modulation of Endothelial Cell Morphology, Function, and Survival Using Anisotropic Nanofibrillar Collagen Scaffolds *Biomaterials*. 2013 Jan 25. doi:pii: S0142-9612
199. Leeper NJ, Zhou M, Nead KT, Syed A, Abella J, Kojima Y, Panchal SN, Diaz Caceres R, Froelicher V, **Cooke JP**, Myers J: Exercise capacity is the strongest predictor of mortality in patients with peripheral arterial disease. *J Vasc Surg*. 2012 Oct 5. doi:pii: S0741-5214(12)01744-2
200. Nead KT, Zhou M, Diaz Caceres R, Sharp SJ, Wehner MR, **Cooke JP** and Leeper NJ: Usefulness of the addition of beta-2-microglobulin, cystatin C and C-reactive protein to an established risk factors model to improve mortality risk prediction in patients undergoing coronary angiography. *Am J Cardiol* Jan 1. doi:pii: S0002-9149(12)02489-7.
201. Hiatt WR, Zakharyan A, Fung ET, Crutcher G, Smith A, Stanford C and **Cooke JP**: Results of a Biomarker Screen to Identify Peripheral Artery Disease in a Practice Setting *Vascular Medicine*, in press, 9-6-12
202. Li J, Huang NF, Zou J, Laurent TJ, Lee JC, Okogbaa J, **Cooke JP**, and Ding S: Conversion of Human Fibroblasts to Functional Endothelial Cells by Defined Factors. *Nature Cell Biology*, re-submitted July 2012
203. Dunn LL, Simpson P, Buckle A, Sieveking DP, Chow RWY, Davies MJ, Stadler N, Lim P, Stocker R, **Cooke JP**, Ng MKC: A Critical Role for Thioredoxin Interacting Protein in Diabetes-Related Impairment of Angiogenesis . *ATVB*, submitted 11-20-12
204. Ghebremariam YT, Huang NF, Kambhampati S, Volz KS, Anslyn EV and **Cooke JP**: Characterization of a Fluorescent Probe for Imaging Nitric Oxide. *Journal of the American Chemical Society* Manuscript submitted 5-13-12.
205. Ahn G-O, Seita J, Lee J, Leeper NJ, **Cooke JP**, Weissman IL, Brown JM: Activation of hypoxia-inducible factor-1 (HIF-1) in myeloid cells is sufficient to mediate angiogenic effects in mice *PNAS* May 9, 2012
206. Rufaihah AJ, Huang NF, Kim J, Herold J, Volz K, Park TS, Lee JC, Zambidis ET, Reijo-Pera R, **Cooke JP**: Human Induced Pluripotent Stem Cell-Derived Endothelial Cells Exhibit Functional Heterogeneity, (subm *ATVB* 5-30-12)

207. Ghebremariam YT, LePendu P, Lee JC, Erlanson DA, Shah NH and **Cooke JP**: An unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor ADMA. Subm, NEJM June 2012
208. LePendu P, Bauer-Mehren, Ghebremariam YT, Iyer SV, Harpaz R, Vasekar AK, Podchiyska T, Ferris TA, Rogers B, Campana E, Vyas V, **Cooke JP** and Shah NH: Proton pump inhibitors increase risk of myocardial infarction: Insights from using clinical notes for pharmacovigilance. Subm, NEJM June 2012

Reviews, Editorials, Letters [120]

1. Vanhoutte PM, **Cooke JP**, Shepherd JT, Flavahan NA: Modulation of postjunctional alpha-adrenergic responsiveness by local changes in temperature. *Clin Sci* 1985; 68 (suppl 10): 121s-123s
2. **Cooke JP**, Safford RE: Progress in the diagnosis and management of aortic dissection. *Mayo Clin Proc* 1985; 61: 147-153
3. **Cooke JP**, Spittell JA: Venous thromboembolism. *Acute Care* 1986; 12:118-164
4. **Cooke JP**, Seward JB, Holmes D: Transluminal pulmonary valvotomy in the adult. *Mayo Clin Proc* 1987; 62:306-311
5. **Cooke JP**, Kazmier FJ, Orszulak TA: The penetrating aortic ulcer: Pathology, diagnosis and management. *Mayo Clin Proc* 1988; 63:718-725
6. Stamler JS, Creager MA, Loscalzo J, **Cooke JP**: Vascular response in diabetics with neuropathic foot lesions. *N Engl J Med* 1988; 319:1155
7. Dzau VJ, **Cooke JP**, Rubanyi G: Significance of endothelial-derived vasoactive substances. *J Vasc Med Biol* 1989; 1:43-45
8. **Cooke JP**, Dzau VJ: Possible role for endothelin in disease states: An alternate hypothesis. *J Vasc Med Biol* 1989; 1:316-319
9. **Cooke JP**, Dzau VJ: The time has come for vascular medicine. *Ann Intern Med* 1990; 112:138-139
10. **Cooke JP**, Dzau VJ: Vascular Academic Award of the National Institutes of Health. *J Vasc Med Biol* 1990; 2:45-46
11. **Cooke JP**: Endothelial dysfunction in disease states. *Current Opinion in Cardiology* 1990; 5:637-644
12. **Cooke JP**, White FV, Donaldson MC: Intermittent claudication and gangrene in a young male smoker. *J Vasc Med Biol* 1990; 2:38-43

13. **Cooke JP**, Creager MA: Endothelial function and its alteration in cardiovascular diseases. *Heart Failure* 1991; 7:45-49
14. **Cooke JP**, Creager MA: Management of the patient with intermittent claudication. *Vasc Med Rev* 1991; 2:19-31
15. **Cooke JP**, Tsao P: Cellular mechanisms of atherogenesis and the effects of nitric oxide. *Current Opinion in Cardiology* 1992; 7:799-804
16. **Cooke JP**, Tsao PS: The role of endothelial dysfunction in restenosis. *Rev Port Cardiol* 1992; 11:889-892
17. Crowley AW, Dzau V, Buttrick P, **Cooke JP**, Devereux RB, Grines CL, Haidet GC, Thames MC: Working group on noncoronary cardiovascular disease and exercise in women. *Med Sci Sports Exercise* 1992; 24:S277-S287
18. **Cooke JP**: Managing lower extremity vascular disease. *Emerg Med* 1993; 25(2):55-60
19. Dzau VJ, Gibbons GH, **Cooke JP**, Omoigui N: Vascular biology and medicine in the 1990's: Scope, concepts, potentials, and perspectives. *Circulation* 1993; 87:705-719
20. **Cooke JP**, Singer AH: Lipid screening: Is measuring cholesterol enough? *Cleveland Clin J Med* 1993; 60:115-118
21. **Cooke JP**, Tsao P: Cytoprotective effects of nitric oxide. *Circulation* 1993; 88:2451-54
22. **Cooke JP**, Tsao P, Singer A, Wang B, Kosek J, Drexler H: Anti-atherogenic effect of nuts: Is the answer NO? *Arch Intern Med* 1993; 153:896-902
23. Ma AO, **Cooke JP**: Luetic aortitis. *J Vasc Med Biol* 1993; 4:331
24. **Cooke JP**: Atherogenesis and the role of endothelial dysfunction. *J Invasive Cardiol* 1994; 6:71-78
25. **Cooke JP**: Normal endothelial function: Beyond EDRF. *Cardiology* (suppl), Feb. 1994
26. **Cooke JP**: Pathobiology of atherosclerosis. *Perspectives in Cardiology* 1994; May, pp. 11-13
27. **Cooke JP**, Candipan R: Vascular biology of restenosis: Insights for therapeutic strategies. *J Intervent Cardiol* 1994; 6:25-35
28. **Cooke JP**: Report to the National Heart, Lung, and Blood Institute from the Stanford Center for Vascular Medicine and Biology. *J Vasc Med Biol* 1994; 5:183-186
29. **Cooke JP**, Dzau VJ: Vascular medicine: an emerging clinical discipline. *J Hong Kong Coll Cardiol* 1994; 2:77-80
30. **Cooke JP**, Tsao PS: Is NO an endogenous anti-atherogenic molecule? *Arterioscler Thromb* 1994; 14:653-655

31. Ma AO, **Cooke JP**: Images in vascular medicine: Effort thrombosis. *J Vasc Med Biol* 1994; 5:87
32. Cooper LT, **Cooke JP**, Dzau VJ: The vasculopathy of aging. *J Gerontology* 1994; 49: B191-196
33. Ma A, **Cooke JP**: Adult hepatic cavernous hemangioma. *J Vasc Med Biol* 1994; 5:74-86
34. Hiatt WR, Hirsch AT, Regensteiner JG, Brass EP and the Vascular Clinical Trialists. Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. *Circulation*. 1995 Aug 1;92(3):614-21
35. **Cooke JP**: Role of nitric oxide in progression and regression of atherosclerosis. *West J Med* 1996; 164: 419-424
36. Hiatt WR, Creager MA, **Cooke JP**, Hirsch AT: Building a partnership between vascular medicine and vascular surgery: A coalition for the future of vascular care. *J Vasc Surg* 1996; 23:915-918
37. Szuba A, **Cooke JP**, Rockson SG: A novel therapy for lymphedema complicated by lymphorrhea. *Vasc Med* 1996; 1:247-250
38. **Cooke, JP**, Theilmeier G: Endothelium-derived nitric oxide: An anti-atherogenic molecule. *Resident & Staff Physician* 1996; Jun pp. 13-28
39. Fearon WF, **Cooke JP**: Acute myocardial infarction in a young woman with systemic lupus erythematosus. *Vasc Med* 1996; 1:19-23
40. Beebe HG, Archie JP, Baker WH, Barnes RW, Becker GJ, Bernstein EF, Brener B, Clagett GP, Clowes AW, **Cooke JP**,...Zarins CK: Concern about safety of carotid angioplasty (editorial). *Stroke* 1996; 27:197-198
41. Hirsch AT, Haidet G, Creager MA, Hiatt WR, Regensteiner JG, **Cooke JP**: Exercise rehabilitation for treatment of claudication (letter; comment). *JAMA* 1996; 275:519-520
42. **Cooke JP**: Therapeutic interventions in endothelial dysfunction: The endothelium as a target organ. *Clin Cardiol* 1997; (VBWG suppl):20:II-45 - II-51
43. **Cooke JP**: The pathophysiology of peripheral arterial disease: Rational targets for drug intervention. *Vasc Med* 1997; 2:227-230
44. **Cooke JP**: Therapeutic interventions in endothelial dysfunction: Endothelium as a target organ. *Clin Cardiol* 1997; 20(suppl), II:45-51
45. **Cooke JP**, Dzau VJ: Nitric oxide synthase: Role in the genesis of vascular disease. *Annu Rev Med* 1997; 48:489-509
46. **Cooke JP**, Tsao PS, Arginine: A new therapy for atherosclerosis? *Circulation* 1997; 95:311-312

47. **Cooke JP**, Dzau VJ: Derangements of the nitric oxide synthase pathway, L-arginine, and cardiovascular diseases (editorial). *Circulation* 1997; 95:379-382
48. Maxwell AJ, **Cooke JP**: Cardiovascular effects of L-arginine. *Current Opinion in Nephrology & Hypertension* (Circulation & Hemodynamics) 1998; 7:63-70
49. Szuba A, **Cooke JP**, Rockson SG: Images in vascular medicine. Phlegmasia coerulea dolens--venous gangrene. *Vasc Med* 1998; 3(1):29-31
50. **Cooke JP**: Is atherosclerosis an arginine deficiency disease? *J Investig Med* 1998; Oct;46(8):377-80 (review)
51. Szuba A, **Cooke JP**: Thromboangiitis Obliterans. An update on Buerger's disease. *West J Med* 1998; Apr 168(4):255-60
52. Maxwell AJ, Tsao PS, **Cooke JP**: Modulation of the nitric oxide synthase pathway in atherosclerosis. *Exp Physiol* 1998; Sep; 83(5):573-84
53. **Cooke JP**: Nutraceuticals for cardiovascular health. *J Am Coll Cardiol* 82(10A) 1998; Nov 19,43S-45S
54. Tsao PS, **Cooke JP**: Endothelial alterations in hypercholesterolemia: more than simply vasodilator dysfunction. *J Cardiovasc Pharmacol* 32 Suppl 1998; 3:S48-53
55. Chen N-G, Abbasi F, Lamendola C, McLaughlin T, **Cooke JP**, Tsao PS, Reaven GM: Mononuclear cell adherence to cultured endothelium is enhanced by hypertension and insulin resistance in healthy non-diabetic volunteers. *Circulation* 1999; 100:940-943
56. **Cooke JP**, Bhatnagar R, Szuba A, Rockson S: Fibroblast growth factor as therapy for critical limb ischemia: A case report. *Vasc Med* 1999; 4(2):89-91
57. **Cooke JP**: The 1998 Nobel Prize in Medicine: Clinical implications for 1999 and beyond. (editorial) *Vasc Med* 1999; 4(2):57-60
58. Maxwell AJ, **Cooke JP**: The role of nitric oxide in atherosclerosis. *Coron Artery Dis* 1999; Jul;10(5):277-86
59. **Cooke JP**: The endothelium: A new target for therapy. *Vasc Med* 2000; 5(1):49-53
60. Szuba A, **Cooke JP**, Yousuf S, Rockson SG: Decongestive lymphatic therapy for patients with cancer-related or primary lymphedema. *Am J Med* 2000 Sep;109(4):296-300
61. **Cooke JP**: Does ADMA cause endothelial dysfunction? *Arterioscl Thromb Vasc Biol* 2000 Sep;20(9):2032-7
62. Boger RH, Bode-Boger SM, Matsuoka H, Miyazaki H, Usui M, Ueda S, Okuda S, Imaizumi T, **Cooke JP**: "Is asymmetric dimethylarginine a novel marker of atherosclerosis?" *Circulation* 2000 Apr 11;101(14):E160-1
63. Wroblewski Lissin L, **Cooke JP**: Maintaining the endothelium: preventive strategies for vessel integrity. *Prev Cardiol.* 2000 Autumn;3(4):172-177

64. **Cooke JP**, Oka RJ: Atherogenesis and the arginine hypothesis. *Curr Atheroscler Rep* 2001 May;3(3):L252-9
65. Lissin LW, **Cooke JP**: Maintaining the endothelium: Preventive strategies for vessel integrity. *Prev Cardiol* 2001; 4:28-37
66. Wroblewski, Lissin L, **Cooke JP**: Soy protein and its constituents offer cardiovascular protection (editorial). *Cardiology Today* 2001
67. Rockson SG, Kramer P, Razavi M, Szuba A, Filardo S, Fitzgerald P, Cooke JP, Yousuf S, DeVault AR, Renschler MF, Adelman DC: Photoangioplasty for human peripheral atherosclerosis: results of a phase I trial of photodynamic therapy with motexafin lutetium. *Circulation* 2001
68. **Cooke JP**, Tsao PS: Go with the flow. *Circulation* 2001 Jun12;103(23):2773-5
69. **Cooke JP**, Losordo DW: Nitric Oxide and Angiogenesis. *Circulation* 2002 May 7;105(18):2133-5
70. **Cooke JP**, Oka RK: Does Leptin cause vascular disease? *Circulation*. 2002 Oct 8;106(15):1904-5.
71. **Cooke JP**: Flow, NO, and atherogenesis. *Proc Natl Acad Sci U S A*. 2003
72. **Cooke JP**: A self-defense against heart attack and stroke. *US News and World Report* Feb 2003 134(4): 58-69
73. **Cooke JP** and Sydow K: A Peculiar Result and a Fanciful Hypothesis regarding L-arginine *Arterioscler Thromb Vasc Biol*. 2003 Jun 1;23(6):1128.
74. Weis M, **Cooke JP**: Cardiac allograft vasculopathy and dysregulation of the nitric oxide synthase pathway. *Arterioscler Thromb Vasc Biol*. 2003 Apr 1;23(4):567-75.
75. Böger RH, Vallance P, and **Cooke JP**: Asymmetric dimethylarginine (ADMA): A key regulator of nitric oxide synthase. *Atheroscler Suppl*. 2003 Dec;4(4):1-3.
76. **Cooke JP**: A novel mechanism for pulmonary hypertension? *Circulation* 2003 108(12): 1420-1
77. **Cooke JP** and Bitterman H: Nicotine and angiogenesis: a new paradigm for tobacco-related diseases. *Ann Med*. 2004;36(1):33-40.
78. **Cooke JP**: ADMA, NO and angiogenesis. *Cardiovascular Research* (in press, 2003)
79. **Cooke JP**: The pivotal role of nitric oxide in vascular health, *Can J Cardiol*. 2004 Aug;20 Suppl B:7B-15B.
80. **Cooke JP**: NO and angiogenesis. *Atherosclerosis* (Suppl) Vol 4/4 pp 53-60

81. **Cooke JP**: Asymmetrical dimethylarginine: the Uber marker? *Circulation*. 2004 Apr 20;109(15):1813-8.
82. **Cooke JP** and Stuhlinger M: Asymmetric dimethylarginine and circulatory disorders in postmenopausal women. *Circulation*. 2004 Feb 10;109(5):e35; author reply e35.
83. Weis M, **Cooke JP**, Lin KY, Panchal SN, Gao SZ, Valantine HA, Kledal TN, Mocarski ES: Sex Hormones and Asymmetric dimethylarginine in transplant arteriosclerosis. *Circulation* July 2004
84. Cooke JP and Cathcart MK: Vascular biology and medicine: From molecules to man. *Vascular Medicine* (2005) 10: 124-125
85. Boger R, **Cooke JP** and Vallance P: ADMA: An emerging cardiovascular risk factor. *Vascular Medicine* 10: S1-2, 2005
86. Sydow K, Mondon CE and **Cooke JP**: Insulin resistance – potential role of the endogenous nitric oxide synthase inhibitor ADMA *Vascular Medicine* 10: S35-43, 2005
87. **Cooke JP**: ADMA: Its role in vascular disease. *Vascular Medicine* 10: S11-17, 2005
88. **Cooke JP**, Marshall J: Mechanisms of Raynaud's disease *Vascular Medicine* 2005 Nov;10(4):293-307.
89. Kielstein J and **Cooke JP**: Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease: comment . *Journal of the American Medical Association* 294:2432, 2005
90. **Cooke JP**: Asymmetric Dimethylarginine (ADMA): an endogenous inhibitor of angiogenesis. *Eur J Clin Pharmacol*. 2006 Feb;62 Suppl 13:115-21
91. Kielstein J, Zoccali C and **Cooke JP**: ADMA: The cardiorenal link? *Circulation* 2006; 114: 242
92. Cooke JP: SVMB presidential address: The time has come for Vascular Medicine. *Vasc Med* 2006 Nov;11(3):177-80.
93. Kielstein J and **Cooke JP**: Should we measure asymmetric dimethylarginine in patients with coronary artery disease? *Clin Chem* 2007; 53(2): 161-3
94. **Cooke JP**: Angiogenesis and the role of the endothelial nicotinic acetylcholine receptor. *Life Sciences*, 2007 May 30;80(24-25):2347-51
95. Potena L, Ferrara R, Mocarski ES, Lewis DB, **Cooke JP**, Grigioni F, Coccolo F, Magnani G, Fallani F, Magelli C, Valantine HA, Branzi A. [Coronary allograft vasculopathy: pathophysiological interaction between the immune system, infections and metabolic syndrome]. *G Ital Cardiol (Rome)*. 2007 Feb;8(2):73-82. Review. Italian.
96. Knowles JW, Assimes TL, Quertermous T, **Cooke JP**: Genetic susceptibility to peripheral arterial disease: a dark corner in vascular biology. *Arterioscler Thromb Vasc Biol*. 2007 Jul 26; [Epub ahead of print]

97. **Cooke JP**: SVMB Presidential address: Vascular medicine: past, present and future. *Vasc Med*. 2007 Aug;12(3):215-8.
98. Creager MA, **Cooke JP**, Olin JW, White CJ: Task Force 11 – training in vascular medicine and peripheral vascular catheter-based interventions endorsed by the Society for Cardiovascular Angiography and Interventions and the Society for Vascular Medicine. *J Am Coll Cardiol*; 51(3): 398-404, 2008
99. Stuehlinger MC, Metzler B, **Cooke JP**: Letter by Stuehlinger et al regarding article, "Metabolic profiling of arginine and nitric oxide pathways predicts hemodynamic abnormalities and mortality in patients with cardiogenic shock after acute myocardial infarction". *Circulation*. 2008 Sep 2;118(10):e149
100. **Cooke JP**: Critical determinants of limb ischemia. *J Am Coll Cardiol*. 2008 Jul 29;52(5):394-6.
101. **Cooke JP** and Ghebremariam Y: Endothelial nicotinic acetylcholine receptors and angiogenesis. *Trends in Cardiovascular Medicine* 2008;18:247–253. PMID: 19232953
102. Wilson AM and **Cooke JP**: Biomarkers in peripheral arterial disease. *J Am Coll Cardiol*. 2010 May 11;55(19):2017-23
103. Leeper NJ, Hunter AL, **Cooke JP**: Stem cell therapy for vascular regeneration: Adult, embryonic and induced pluripotent stem cells. *Circulation* 2010;122:517-526
104. **Cooke JP**: DDAH: A target for vascular therapy? *Vasc Med*. 2010 Apr 12. [Epub ahead of print]
105. Dunn LL, Buckle AM, **Cooke JP** and Ng MKC: The emerging role of the thioredoxin system in angiogenesis. *Arterioscler Thromb Vasc Biol*. 2010 Nov;30(11):2089-98
106. Axtell AL, Gomari FA, **Cooke JP**: Assessing endothelial vasodilator function with the Endo-PAT 2000." *J Vis Exp* 2010; 44: pii: 2167. doi: 10.3791/2167.
107. Leeper N and **Cooke JP**: MicroRNA and mechanisms of impaired angiogenesis in diabetes mellitus. *Circulation*. 2011 Jan 25;123(3):236-8
108. Lee J and **Cooke JP**: The role of nicotine in the pathogenesis of atherosclerosis. *Atherosclerosis* 2011 Apr;215(2):281-3
109. **Cooke JP** and Ghebremariam Y.T: Dietary nitrate, nitric oxide and restenosis. *J Clin Invest*. 2011 Apr 1;121(4):1258-60
110. Leeper NJ, Lee JT, **Cooke JP**: Two decades of progress in Vascular Medicine. *Am J Med* 2011 Jun 16 [Epub ahead of print].
111. **Cooke JP**, Ghebremariam YT. DDAH Says NO to ADMA. *Arterioscler Thromb Vasc Biol*. 2011 Jul;31(7):1462-4.

112. **Cooke JP**: Lymphangiogenesis: A potential new therapy for lymphedema? *Circulation*, Jan 24, 2012
113. Leeper NJ, Kullo IJ, **Cooke JP**: Genetics and peripheral arterial disease. *Circulation*. 2012 Jun 26;125(25):3220-8
114. Vanhoutte PM, **Cooke JP**, Cohen RA: In memoriam of John T. Shepherd, MD DSc. *Circulation* 2012 Jan 17;125(2):393-4
115. Volz KS, Miljan E, Khoo A and **Cooke JP**: Development of pluripotent stem cells for vascular therapy. *Vascul Pharmacol*. 2012 May-Jun;56(5-6):288-96
116. **Cooke JP** and Lee J: Nicotine and pathological angiogenesis. *Life Sciences*, in press, June 2012.
117. Huang NF, Okogbaa J, Babakhanyan A, and **Cooke JP**: Bioluminescence imaging of stem cell-based therapeutics for vascular regeneration. *Theranostics*, 2012;2(4):346-54.
118. **Cooke JP**: Imaging vascular nicotine receptors: a new window onto vascular disease. *JACC Cardiovasc Imaging*. 2012 May;5(5):537-9
119. Ghebremariam YT and **Cooke JP**: The Nitric Oxide pathway as a novel target in Pulmonary Diseases. *AJRCCM* (subm 5-13-12)
120. Wong WT, Huang NF, Botham CM, Sayed N, **Cooke JP**. Endothelial cells derived from nuclear reprogramming. *Circ Res*. 2012 Oct 26;111(10):1363-75

Policy and Position Papers, Committee Reports[9]

1. European Working Group on Medical Angiology (Bartolo M, Boccalon H, Bollinger A, Breddin K, Catalano M, Clement D, Coccheri S, **Cooke JP**, Diamantopoulos E, Ehringer H, Fagrell B, Linhart J, Mahler F, Nizankowski R, Rieger H, Strano A, Tamburino G, Tooke J): The case for the specialty of medical angiology. *Intl Angiol* 1991; 10:199-201, Oct-Dec
2. European Working Group on Medical Angiology (Members: ... **Cooke JP**, et al): Proposed training requirements for medical angiology fellows. *Intl Angiology* 1993; 12:323-325
3. **Cooke JP**, Olin JW, Joyce JW: Guidelines for a training program in vascular medicine: A position paper from the Society of Vascular Medicine and Biology. *J Vasc Med Biol* 1994; 5:1-4
4. Abenheim L, Kurz X, Norgren L, Clément D, and the VEINES Task Force (**Cooke JP** et al): *The Management of Chronic Venous Disorders of the Leg (CVDL): An Evidence-Based Report of an International Task Force*. Montreal: McGill University, Sir Mortimer B. Davis - Jewish General Hospital, 1996, 194 pp.
5. Kurz X, Kahn SR, Abenheim L, Clement D, Norgren L, Baccaglini U, Berard A, **Cooke JP**, et. al.: Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the VEINES task force. Venous insufficiency epidemiologic and economic studies. *Int Angiol* 1999; Jun;18(2):83-102.6
6. McKay CR, Rich MW, Vlietstra RE, Kitzman DW, Fleg JL, Krumholz HM, Lakatta EG, **Cooke JP**, Cannon CP, Ezekowitz MD, Frohlich ED, Jalife J, Kass DA, Kottke BA,

- Muller JE, Saltin B, Shen WK, Somers VK. Executive Summary: Pivotal research in cardiovascular syndromes in the elderly. *Am J Geriatr Cardiol* 2000 Oct;9(5):243-250
7. Creager MA, **Cooke JP**, Olin JW, White CJ. Task Force 11: Training in vascular medicine and peripheral catheter-based interventions. ACC revised recommendations for training in adult cardiovascular medicine core cardiology training II (COCATS 2). Steering Committee: Beller GA, Bonow RO, Fuster V. *J Am Coll Cardiol* 2002;39:1242-1246.
 8. Creager MA, Hirsch AT, **Cooke JP**, Olin JW, Jaff MR, Rooke T, and Halperin JL: Postgraduate training in vascular medicine: proposed requirements and standards. *Vascular Medicine*. 2003;8(1):47-52.
 9. **Cooke JP**: Smoking and the endothelium, in *How tobacco smoke causes disease: The biology and behavioral basis for smoking-attributable disease. A report of the Surgeon General*, pp.370-374. Rockville MD:US Department of Health and Human Services, Public Health Service, Office of the Surgeon General, 2010, 704pp.

Books [4]

1. **Cooke JP**: *Alpha Adrenergic Receptors in Vascular Smooth Muscle: Characterization of Subtypes and Modulation of Response by Alteration in Temperature and Calcium Availability* (thesis). Rochester, MN: Mayo Graduate School, 1984.
2. **Cooke JP**, Frohlich ED (eds). *Current Management of Hypertensive and Vascular Diseases*. Philadelphia: Mosby - Year Book, Inc., 1992, 380 pp.
3. Rubanyi GM, Dzau VJ, **Cooke JP**: *Vascular Protection. Molecular Mechanisms, Novel Therapeutic Principles and Clinical Application*. Taylor & Francis, London UK 2002
4. **Cooke JP**, Zimmer J: , *The Cardiovascular Cure: Your self-defense against Heart Attack and Stroke*. Random House 2002

Book chapters [49]

1. Vanhoutte PM, **Cooke JP**: Vascular responsiveness in hypertension. In: Spittell JA (Editor). *Clinical Medicine*, vol. 7, pp. 1-13, New York: Harper & Row, 1985
2. **Cooke JP**, Stamler J, Andon NA, Davies PF, Mendelsohn ME, Loscalzo J: Flow-mediated endothelium-dependent effects on platelet and vascular reactivity. In: Rubanyi G, Vanhoutte PM (eds). *Endothelium-Derived Relaxing Factors*, vol 1, pp.244-253, Basel, Switzerland: Karger Press, 1990
3. **Cooke JP**, Dzau VJ, Creager MA: Endothelial dysfunction in hypercholesterolemia is corrected by L-arginine. pp. 173-184. In: Drexler H, Zeiher AM, Bassenge E, Just H (eds). *Endothelial Mechanisms of Vasomotor Control*. New York: Springer-Verlag, 1991
4. Creager MA, **Cooke JP**, Tucker JI, Dzau VJ: Lipoproteins and endothelial dysfunction. (pp. 251-262). In: Rubanyi GM (ed). *Cardiovascular Significance of Endothelium-Derived Vasoactive Factors*. Mt. Kisco, NY: Futura Publishing Co., 1991

5. **Cooke JP**: Chronic arterial occlusive disease: Medical management. In: **Cooke JP**, Frohlich ED (eds). *Current Management of Hypertensive and Vascular Diseases*. pp. 203-208, St. Louis: BC Decker, 1992
6. **Cooke JP**: Endothelium-derived factors and peripheral vascular disease. In: Spittell JA Jr. (Ed). *Contemporary Issues in Peripheral Vascular Disease* pp. 3-17 (Brest AN, ed: Cardiovascular Clinics 22/3). Philadelphia: FA Davis, 1992
7. **Cooke JP**, Dzau VJ: The pathophysiology of vasospasm. In: *Vascular Medicine: A Textbook of Vascular Biology and Diseases*. pp. 371-389, Boston: Little, Brown, 1992
8. **Cooke JP**, Rooke TW: Lymphedema. In: *Vascular Medicine: A Textbook of Vascular Biology and Diseases* pp. 1099-1113, Boston: Little, Brown, 1992
9. **Cooke JP**, Santosa AC: Endothelium-derived relaxing factor (nitric oxide) and vascular tone. In: Alexander NJ, d'Arcangues C (eds). *Steroid Hormones and Uterine Bleeding* pp. 225-240. Washington DC: AAAS Press, 1992
10. Dzau VJ, Pratt RE, **Cooke JP**: Endothelin as a growth factor in vascular remodeling and vascular disease. In: *Endothelin* pp. 137-143, London: Oxford University Press, 1992
11. Rossitch E, **Cooke JP**: Complications of intracranial aneurysms. In: **Cooke JP**, Frohlich ED (eds). *Current Management of Hypertensive and Vascular Diseases* pp. 153-156, Philadelphia: BC Decker, 1992
12. Singer A, **Cooke JP**: Aortic aneurysm. In: **Cooke JP**, Frohlich ED (eds). *Current Management of Hypertensive and Vascular Diseases*. Philadelphia: BC Decker, 1992
13. Spittell PC, **Cooke JP**: Mesenteric ischemia. In: **Cooke JP**, Frohlich ED (eds). *Current Management of Hypertensive and Vascular Diseases* pp. 188-194, Philadelphia: BC Decker, 1992
14. Thiadens SRJ, Rooke TW, **Cooke JP**: Lymphedema. In: **Cooke JP**, Frohlich ED (eds). *Current Management of Hypertensive and Vascular Diseases* pp. 314-319, Philadelphia: BC Decker, 1992
15. **Cooke JP**: Atherogenesis. In: Izzo JP Jr, Black HR (eds). *Hypertension Primer* ch. B29, pp. 119-121, Dallas, TX: American Heart Association, 1993
16. Dzau VJ, Tsao PS, **Cooke JP**: Cellular mechanisms of vasodilation. In: O'Rourke M, Safar ME, Dzau VJ (eds). *Arterial Vasodilation: Mechanisms and Therapy* pp. 200-207, London: Edwin Arnold, 1993
17. Tsao PS, Dzau VJ, **Cooke JP**: Nitrates: Mechanisms of action and tolerance. In: O'Rourke M, Safar ME, Dzau VJ (eds). *Arterial Vasodilation: Mechanisms and Therapy* pp. 208-215, London: Edwin Arnold, 1993
18. **Cooke JP**, Ma AO: Medical therapy of peripheral arterial occlusive disease. In: Gewertz B (ed). *Surg Clin N Amer* 75:569-579, 1995

19. Ma AO, **Cooke JP**: Medical management of peripheral arterial occlusive disease. In: Ouriel K (ed). *Lower Extremity Vascular Disease*. New York: WB Saunders, 1995
20. **Cooke JP**, Tsao PS: Endothelium-derived relaxing factor: An overview. In: Sowers JR (ed). *Contemporary Endocrinology: Endocrinology of the Vasculature*. Ch, 1, pp. 3-19, Totowa, NJ: Humana Press, 1996
21. **Cooke JP**, Rooke TW: Lymphedema. In: Loscalzo J, Creager MA, Dzau VJ, editors. *Vascular Medicine: A Textbook of Vascular Biology and Diseases* 2nd ed. Boston: Little, Brown and Company pp. 1133-46, 1996
22. **Cooke JP**: The role of the endothelium in atherosclerosis. In: Schultheiss HP, Schwimmbeck P (eds). *The Role of Immune Mechanisms in Cardiovascular Disease*. pp. 194-204, Berlin, Springer-Verlag, 1997
23. **Cooke JP**, Bhatnagar R: Pathophysiology of atherosclerotic vascular disease. In: *Disease Management & Outcomes* 2 (suppl 1): "A Global Approach to Vascular Disease." (Clement DL, (ed). Auckland, New Zealand, ADIS International, pp. 1-8, 1997
24. **Cooke JP**, Tsao PS: Endothelial alterations in atherosclerosis: The role of nitric oxide. In: Webb D, Vallance P (eds). *Endothelial Function in Hypertension*. pp. 29-38, Heidelberg, Springer-Verlag, 1997
25. **Cooke JP**, Tsao PS: The role of endothelium-derived nitric oxide in atherosclerosis. In: Nicolaides A, Novo S (eds). *Advances in Vascular Pathology 1997*. pp. 3-14, Amsterdam, Elsevier, 1997
26. **Cooke JP**: Lymphedema. In: Rosenbaum EH, Rosenbaum IR (eds). *Everyone's Guide for Cancer Patients and Their Families*. pp. 29-31, Kansas City, KS, Andrews McNeil, 1998
27. Maxwell AJ, **Cooke JP**: Regulation of vasomotor tone. In: Topol E (ed). *Textbook of Cardiovascular Medicine*. Philadelphia, Lippincott-Raven, 1997
28. Rockson SA, **Cooke JP**: Peripheral arterial insufficiency: Mechanisms, natural history and therapeutic options. In: Schrier RW, Baxter JD, Dzau VJ, Fauci AS (eds). *Advances in Internal Medicine*, v. 43, pp. 253-277, St. Louis, Mosby-Year Book, 1998
29. Adimoolam S, **Cooke JP**: Endothelium-derived nitric oxide: An antiatherogenic molecule. In: Panza JA, Cannon RO (eds). *Endothelium, Nitric Oxide and Atherosclerosis* pp. 257-268, New York: Futura Pub., 1999
30. Maxwell AJ, **Cooke JP**: L-arginine, its role in cardiovascular therapy. In: Loscalzo J, Vita JA (eds). *Contemporary Cardiology, vol. 4: Nitric Oxide and the Cardiovascular System*, pp. 547-585, Humana Press, New Jersey, 2000
31. **Cooke JP**, Mont-Reynaud RL, Tsao PS, Maxwell AJ: Nitric oxide and vascular disease. In: Ignarro L (ed). *Nitric Oxide: Biology and Pathobiology* pp. 759-784. Academic Press, 2000
32. Hiatt WR, **Cooke JP**: Atherogenesis and the medical management of atherosclerosis. *Rutherford's Text of Vascular Surgery*, pp. 333-350. W.B. Saunders Co., 2000

33. **Cooke JP**, Oka RK: Dyslipidemia in peripheral arterial disease: Insights and advances in therapy. In: Hirsch A (ed). *Primary Care Series: Peripheral Arterial Disease and Intermittent Claudication* Excerpta Medica, Inc., 2001
34. **Cooke JP**: Mechanisms of atherosclerosis in peripheral arterial disease. In: *Peripheral Arterial Disease Handbook*, CRC Press, 2001
35. **Cooke JP**, Szuba A: Lymphedema. In: Rosenbaum EH and Rosenbaum I (eds) *Supportive Cancer Care: The Complete Guide for Patients and their Families*. Sourcebooks Inc., Illinois, 2001
36. **Cooke JP**: Atherosclerosis. In: Breslow L (ed). *Encyclopedia of Public Health* Macmillan Reference USA, New York, 2002
37. **Cooke JP**, Heeschen C: Therapeutic angiogenesis and nitric oxide. Rubanyi G, Dzau V, Cooke JP (eds). *Vascular Protection. Molecular Mechanisms, Novel Therapeutic Principles and Clinical Application*. Pp. 401-412, Taylor & Francis, London UK 2002
38. Maxwell AJ, **Cooke JP**, Anderson B, Zapien MP, and Ramos H: A novel nutritional therapy for peripheral arterial disease. In, Rubanyi G, Dzau V, **Cooke JP** (eds), *Vascular Protection. Molecular Mechanisms, Novel Therapeutic Principles and Clinical Application*. Pp. 413-430, Taylor & Francis, London UK 2002
39. Ignaffo R, Rosenbaum EH, Dollinger M, Rosenbaum IR, Festa F, **Cooke JP**, Szuba A: Coping with the side effects of chemotherapy. In: Rosenbaum EH, Rosenbaum IR (eds). *Everyone's Guide to Cancer Therapy: How Cancer is diagnosed, treated and managed day to day*. pp. 161-75, Kansas City, MO, Andrews McMeel, 2003
40. Hiatt WR, **Cooke JP**: Atherogenesis and the medical management of atherosclerosis. *Rutherford's Text of Vascular Surgery*, forthcoming.
41. Weis M and **Cooke JP**: Statins and angiogenesis. In, *Statins: Understanding Clinical Use*, pp. 271-284, Ed. J. Mehta Publ. Elsevier, Philadelphia PA 2004
42. **Cooke JP**. The diversity of vascular disease: a clinician's perspective. In, *Endothelial Cells in Health and Disease*. Ed. W. C. Aird. Publ. Taylor and Francis Group 2005
43. Rockson S and **Cooke JP**: Diseases of the Lymphatic Circulation In: "Vascular Medicine: A Companion to Braunwald's Heart Disease. Ed: Creager MA, Dzau VJ, Loscalzo J. Publ: Elsevier. November, 2005
44. Nair N, Valantine H and **Cooke JP**: Transplant Arteriosclerosis: Role of Nitric Oxide Synthase. In *The Biochemistry of Atherosclerosis*, ed. S.K. Cheema, publ. Springer, NY 2006
45. **Cooke JP**, Szuba A, Rosenbaum EH: Lymphedema. In: Rosenbaum EH, Spiegel D, Fobair P, Gautier H (eds). *Everyone's Guide to Cancer Therapy: A Roadmap for Better Health*. pp. 226-229, Kansas City, MO, Andrews McMeel, 2007

46. **Cooke JP**, Hunter AL: Non-viral reprogramming: Toward a safer induced pluripotent stem cell. *Advances in Wound Care: Volume 2*, Wound Healing Society Yearbook Series. Ed. Chandan K. Sen. Publ. Mary Ann Liebert, Inc., New Rochelle, NY
47. Wong WT and **Cooke JP**: Nutritional impact on the nitric oxide pathway. In, Nitrates and Nitrites in Human Health and Disease. Eds. Nathan S. Bryan and Joseph Loscalzo. Publ. Springer/Humana Press 2011
48. Wilson A, Ardehali R and **Cooke JP**. (2011). Peripheral vascular disease. In: R. Ardehali, P. Wang, M. Perez (eds.), A Practical Approach to Cardiovascular Medicine (Chap. 12, pp154-162). Hoboken, NJ: Wiley-Blackwell. ISBN-13: 978-1405180399
49. Lee JC, Huang NF, **Cooke JP**. Hindlimb Ischemia. In, Manual of research techniques in cardiovascular medicine . Ed. Robert Bolli (2012)

Book reviews [2]

1. **Cooke JP**: Mechanoreception by the Vascular Wall (Ed. Rubanyi GM: Armonk, NY: Futura, 1993, 250 pp). *J Vasc Surg*
2. **Cooke JP**: *Endothelial Biomedicine*. *Circulation* 2008;117:e148

Abstracts [selected from a list of over 270]

1. Kimura E, Nair N, Harada R, Narasimhan B, Meng X-Y, Zhang F, Varasteh B, Fung E, Cooke JP: Proteomic Profiling Reveals the Plasma Beta 2 Microglobulin is a marker for PAD ACC 2006
2. Ng M.K.C., Assimes T., Wang B.Y., McGee S., Harada R.K., Yeung A.C., Narasimhan B., Olin J.W. and Cooke J. P. Plasma Asymmetric Dimethylarginine is an Independent Marker for the Presence and Severity of Peripheral Artery Disease ACC 2006
3. Wu J, Pitsiouni M, Adams C, Cooke ME, Peter C, Konishi H, Cooke JP: Signal-transduction of nAChR-mediated endothelial cell migration and proliferation ACC 2006
4. Ng MK, Chang E, Wu J, Wang B-Y, Katzenburg-Clark, Ishii-Watabe A, Cooke JP: A central role for nicotinic cholinergic regulation of growth factor-induced endothelial cell migration – novel insights into angiogenesis. American Heart Association, November 2005 Dallas Tx
5. Konishi H, Wu J, Cooke JP: Chronic exposure to nicotine downregulates ischemia-induced angiogenesis. American Heart Association, November 2005 Dallas Tx
6. Wu JC, Konishi H, Peter C, Cooke JP: A novel mechanism for ischemia-induced neuropathy. American Heart Association, November 2005 Dallas Tx

7. Harada RK, Wang B, Kimura E, Nair N, Cooke JP: Chronic Elevations of Asymmetric Dimethylarginine in Patients with Peripheral Arterial Disease Oppose Exercise-Facilitated Nitric Oxide Bioavailability American Heart Association, November 2005 Dallas Tx
8. Wu JC, Adams C, Pitsiouni M, Peter C and Cooke JP: Study of signal-transduction pathway of nAChR-mediated endothelial cell migration and proliferation. Society for Vascular Medicine and Biology, June 2007
9. Wilson AM, Weatherby C, Beck KR, Assimes T, Ocampo O, Olin J and Cooke JP: Reduced ankle brachial index is associated with adverse long term prognosis in patients referred for coronary angiogram. Society for Vascular Medicine and Biology, June 2007
10. Pitsouni M, Peter C, Holweg C, Kielstein J, Wu J, Clarke-Katzenburg R, Kengatharan K and Cooke JP: "The role of Acetylcholine release in cancer cell growth and vascularization" Society for Vascular Medicine and Biology, June 2007 (Chosen for Young Investigator Award)
11. Wilson AM, Harada R, Nair N, Virani S, Tavana H, Oka R and Cooke JP: Asymmetric dimethyl arginine (ADMA) levels correlate with ankle brachial index and claudication time in patients with peripheral arterial disease independent of other risk factors. Society for Vascular Medicine and Biology, June 2007 (Chosen for Young Investigator Award)
12. Li Z, Wu J, Cooke JP and Wu J: Endothelial Progenitor Cells from Murine Embryonic Stem Cells: Isolation and Transplantation for Myocardial Infarction. Society for Vascular Medicine and Biology, June 2007 (Chosen for Young Investigator Award)
13. Wu J et al, Cooke JP: Expression of alpha7 and alpha9 nAChR helps Balance Angiogenesis in Endothelial Cells. Society for Vascular Medicine, June 2007 (Chosen for Young Investigator Award)
14. Wu J et al, Cooke JP: Expression of alpha7 and alpha9 nAChR helps Balance Angiogenesis in Endothelial Cells. Society for Vascular Medicine, June 2008
15. Niiyama H et al, Cooke JP: The Role of Nicotinic Acetylcholine Receptor in Atherosclerosis Society for Vascular Medicine, June 2008
16. Wilson A et al, Cooke JP: 'Deep' Plasma Proteomic Profiling Reveals Increased Expression of Amyloidogenic Proteins in Patients with Peripheral Arterial Disease. Society for Vascular Medicine, June 2008
17. Peter C et al, Cooke JP: Vascular Endothelial Cells Express the "Muscle-Specific" Nicotinic Acetylcholine Receptor Signaling Complex Society for Vascular Medicine, June 2008
18. Huang N et al, Cooke JP: A Comparison of Embryonic Stem Cell Delivery Modalities for Treatment of Critical Limb Ischemia. Society for Vascular Medicine, June 2008
19. Fung E et al, Cooke JP: A Biomarker Panel for Peripheral Arterial Disease. Society for Vascular Medicine, June 2008

20. Sadrzadeh A et al, Cooke JP: Lifetime Recreational Activity Predicts Peripheral Arterial Disease. Society for Vascular Medicine, June 2008 (Chosen for Young Investigator Award)
21. Shin D et al, Cooke JP: Plasma Asymmetric Dimethylarginine Levels Predict Mortality and Major Adverse Cardiovascular Events in Patients With Peripheral Arterial Disease Society for Vascular Medicine, June 2008 (Chosen for Young Investigator Award)
22. Yang W et al, Cooke JP: Cell-Free Production of Nona-Arginine Transcription Factor Fusion Proteins for Non-Viral Modulation of Gene Expression. American Institute of Chemical Engineers, November 2009.
23. Lee J, Hunter A, Yang W, Patel K, Reijo Pera R, Swartz J, Goldman R, Cooke JP. Transcriptional regulation of iPSC induction: Virus versus Protein Approach. ISCCR 2010

Invited presentations [selected from 279]

1. **Cooke JP:** "The 11th Annual Terry Kavanagh Lecture: Endothelial Health is a Critical Determinant of Cardiovascular Health", Canadian Association of Cardiac Rehabilitation, Annual Meeting Oct 27, 2003
2. **Cooke JP:** "ADMA: An emerging risk factor for cardiovascular disease" U. Penn Cardiology Grand Rounds 9-11-03
3. **Cooke JP:** "Plenary Lecture: The Pivotal Role of Nitric Oxide in Determining Vascular Health" Canadian Vascular Biology Working Group Meeting Vancouver BC August 16 2004
4. **Cooke JP:** "Role of the nACh receptor in angiogenesis and stem cell mobilization" The 1st Seoul Conference on Cardiovascular Research. Mar 18-19, 2005, Seoul Korea
5. **Cooke JP:** "Cholinergic Angiogenesis". The 69th Annual Scientific Meeting of the Japanese Circulation Society. March 20, 2005 Yokohama Japan
6. **Cooke JP:** "ADMA: An endogenous regulator of NO synthase. Lessons from the DDAH transgenic mouse." Fukuoka, Japan Mar 21, 2005
7. **Cooke JP:** "Hypertension: is it an endothelial disorder?" "Interdisciplinary Congress on Hypertension" April 21-23, 2005, Wroclaw, Poland
8. **Cooke JP:** ADMA: An endogenous regulator of NO synthase. Gordon Conference on Atherosclerosis. U of New England, Portland Maine June 23, 2005
9. **Cooke JP:** "Genomic and proteomic applications to discovery in PAD". Keynote Lecture, Eurochap 2005, Glasgow Scotland, Oct 26, 2005.

10. **Cooke JP:** “Role of the nAChR in Pathological Angiogenesis” Victor Dzau Lecture, Tokyo Japan Jan 6, 2006
11. **Cooke JP:** “State-of-the-Art: Novel Therapies for Peripheral Arterial Disease”. American College of Cardiology, Atlanta March 12, 2006
12. **Cooke JP:** Insights into Pulmonary Vascular Disease from Vascular Biology and Medicine”. Inaugural John Vane Memorial Symposium. London, UK Mar 30 2006
13. **Cooke JP:** “Role of the nicotinic acetylcholine receptor in pathological angiogenesis” 2nd International Non-neuronal acetylcholine symposium, Mainz Germany, Sept 1, 2006
14. **Cooke JP:** “A novel angiogenic pathway mediated by the endothelial nAChR”, Plenary lecture, American Heart Association Young Investigators Forum, San Francisco, Sept 29 2006
15. **Cooke JP:** “Role of ADMA in Vascular Disease”, plenary lecture, 3rd International ADMA symposium, London England, December 1, 2006
16. **Cooke JP:** “An endothelial nACh receptor, and its role in angiogenesis”. Wound Healing, Science and Industry, St Thomas, December 8 2006
17. **Cooke JP:** “Nicotine and pathological angiogenesis” Society for Research on Nicotine and Tobacco, Austin Texas, February 22 2007
18. **Cooke JP:** “Angiogenesis and tobacco-related disease: role of the endothelial nicotinic acetylcholine receptor”. Visiting Professor, Ohio State University, May 22, 2008
19. **Cooke JP:** “Therapeutic angiogenesis and vascular regeneration: the promise of induced pluripotential cells”. Visiting Professor and invited speaker for the annual Grollman Lecture, University of Virginia, Tuesday May 5, 2009.
20. **Cooke JP:** “Optimizing nuclear reprogramming of human somatic cells with cell permeant peptides (CPP). IBMS, Academia Sinica, Taipei Taiwan, March 10-12, 2010
21. **Cooke JP:** “Vascular Regeneration: Cell Therapies to Restore Perfusion”. Cardiology Grand Rounds, Massachusetts General Hospital, May 5, 2010
22. **Cooke JP:** “Induced pluripotential stem cells for vascular regeneration”, Robert Muller Lecture, UniversitatsMedizin Mainz Germany, Sept 8, 2010
23. **Cooke JP:** “ADMA: an endogenous NOS inhibitor and CV Risk factor ”, plenary lecture, 33rd Annual Meeting of the Japanese Society of Hypertension, Oct 14 2010.
24. **Cooke JP:** “Nicotine and angiogenesis”. FDA Workshop on Risks and Benefits of Long-Term Use of Nicotine Replacement Therapy Products. Bethesda, MD Tues Oct 26, 2010.
25. **Cooke JP:** “Biomarkers for Peripheral Arterial Disease”“Joint Session of the Egyptian Society of Cardiology and the ACC: Peripheral Vascular Disease. American College of Cardiology, Invited speaker and moderator, April 5, 2011.

26. **Cooke JP:** "Nuclear reprogramming for vascular regeneration" May 24, 2011. Visiting Professor at Division of Cardiovascular Medicine, Brigham and Womens Hospital, Boston
27. **Cooke JP:** "Nuclear reprogramming for vascular regeneration" At the 6th European Meeting for Vascular Biology & Medicine, Kraków, Poland Sept 21-24, 2011
28. **Cooke JP:** "Nuclear reprogramming for vascular regeneration" At the Symposium "Molecular Organisation of Immune Cell Communication" September, 23-24, 201, Magdeburg Germany.
29. **Cooke JP:** "Vascular regeneration: nuclear reprogramming and transdifferentiation to improve perfusion and tissue function". May 9, 2012. Visiting Professor at Division of Cardiovascular Medicine, Brigham and Womens Hospital, Boston

Patents, issued and filed [31]

1. Loscalzo J, **Cooke JP:** *S-nitrosocaptopril compounds and the use thereof*. US Patents No. 5,025,001 (Issued: 6/18/91) and 5,187,183 (Issued: 2/16/93). Assignee: Brigham and Women's Hospital. This patent protects the composition and use of s-nitrosocaptopril, which has the property of a nitrovasodilator and an angiotensin converting enzyme inhibitor. Licensee: NitroMed
2. **Cooke JP**, Dzau VJ, Gibbons G: *Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity*. US Patent No. 5,428,070 (Filed: 6/11/93, Issued: 6/27/95). Assignee: Stanford University. This patent protects the use of arginine or NOS gene therapy for vascular disease, and the claims include the use of arginine-enriched health bar. Licensee: United Therapeutics; Thermolife.
3. **Cooke JP**, Dzau VJ, Gibbons G: *"Enhancement of Vascular Function by Modulation of Endogenous Nitric Oxide Production or Activity"*. U.S. Patent 5,861,168 (Filed: 12/16/96, Issued: 12/22/98). Assignee: Stanford University. This application protects the use of arginine, specifically in the body of a stent to inhibit restenosis. Licensee: United Therapeutics.
4. **Cooke JP**, Dzau VJ, Gibbons G: *"Enhancement of Vascular Function by Modulation of Endogenous Nitric Oxide Production or Activity"* U.S. Patent 5,891,459 (Filed: 11/9/95, Issued: 4/6/99). Assignee: Stanford University. Protects the use of arginine and other nitric oxide enhancers as dietary supplements in improving vascular function. Licensee: United Therapeutics; Thermolife
5. **Cooke JP**, Schwarzacher S, Lim TT, Yeung AC: *Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury*. US Patent No. 5,852,058 (Filed: 8/12/96, Issued: 1/19/98). Assignee: Stanford University This patent protects a method of performing angioplasty or atherectomy whereby L-arginine or L-lysine is

- introduced into the vessel wall during the procedure to inhibit restenosis. Licensee: United Therapeutics.
6. Maxwell AM, **Cooke JP**: *Enhancement of Exercise Performance by Augmenting Endogenous Nitric Oxide Product or Activity*. US Patent No. 6,117,872 Assignee: Stanford University. This application protects the use of arginine and other nitric oxide enhancers to enhance aerobic exercise performance. Licensee: United Therapeutics; Thermolife.
 7. Maxwell AM, **Cooke JP**: *Arginine or Lysine containing Fruit HealthBar Formulation* U.S. Patent 6,063,432: (Filed 5/19/98. Issued: 5/16/2000). Assignee: Cooke Pharma. This patent protects the specific formulation of the HeartBar and related formulations. Licensee: United Therapeutics; Thermolife
 8. Balint R, Mutz R & **Cooke JP**: *Assay for Asymmetric N, N-dimethyl-L-arginine*. U.S. Patent 09/495,553(Filed 2/5/99; Issued 3/19/02). Assignee: PRI/Cooke Pharma. This application seeks to protect an enzymatic method of detecting ADMA levels. Licensee: United Therapeutics.
 9. **Cooke JP**, Fathman GC, Rothbard JB, Uemura S, Robbins RC, Kown MC: *Method and composition for inhibiting cardiovascular cell proliferation*. US Patent No. 6,605,115 (Filed 6-5-99, issued August 12, 2003). Assignee: Stanford University. This patent protects the composition and use of arginine oligopeptides which have unexpected utility in transporting large molecules across cell membranes. Licensee: Lumen.
 10. **Cooke JP**, Jang J, Tsao P and Heeschen C : *Nicotine in Therapeutic Angiogenesis and Vasculogenesis*. US Patent No. 6,417,205 (filed 7-28-99, issued 7-9-02). Corresponding patents have issued in Australia (AU 781084) and Canada, and are pending in Japan and Europe. Assignee: Stanford University. This patent protects the use of nicotine and nicotinic agonists for therapeutic angiogenesis. Licensee: CoMentis.
 11. **Cooke JP**, Jang J, Tsao P, Heeschen C, Pathak A and Johnson F : *Nicotine receptor agonists in stem cell and progenitor cell recruitment*. U.S. Patent # No. 6,720,340 B1 (filed 7-28-00, issued Apr 13, 2004). Corresponding patents have issued in Australia (AU 778386) and Canada, and are pending in Japan and Europe. Assignee: Stanford University. This patent protects the use of nicotine and nicotinic agonists for therapeutic amplification for stem cells and progenitors. Licensee: CoMentis.
 12. **Cooke JP**, Dzau J, Gibbons GH: *Enhancement of vascular function by modulation of endogenous nitric oxide production or activity*. U.S. Patent # 6,337,321 B1 (Filed May 8, 1998; Issued Jan. 8, 2002). This patent protects the use of gene therapeutic uses of NO synthase in a variety of constructs and transfection vehicles. Licensee: Megabios.
 13. **Cooke JP**, Heeschen C, Weis M: *Methods of reducing angiogenesis* (U.S. Patent # 7,045,534 (filed Feb 12, 2002; Issued May 16, 2006). Corresponding patents have issued in Australia (No. 2003214991), and are pending in Canada, Japan and Europe. The invention relates to the reduction of pathological angiogenesis (eg. As in tumors,

- atherosclerotic plaque, diabetic retinopathy), using antagonists of the nicotinic pathway. Licensee: CoMentis
14. **Cooke JP**, Balint RF: Proteins and methods useful for assessing risk of cardiovascular disease (filed in US April 30, 2002; filed in Europe May 30, 2003). The invention relates to the measurement of ADMA using mutant forms of DDAH. Licensee: United Therapeutics
 15. **Cooke JP**, Tsao P, Stuehlinger M, Zhang Y: Novel assay for homocysteine measurement (submitted to the Patent Office Sept 2002). Licensee: Inbios
 16. **Cooke JP**, Dzau VJ, Gibbons G: *“Enhancement of Vascular Function by Modulation of Endogenous Nitric Oxide Production or Activity”* U.S. Patent # 6,642,208 B2 (Filed Aug 15, 2001; issued Nov 4, 2003). This patent protects the use of gene therapeutic uses of NO synthase for reducing vascular inflammation.
 17. **Cooke JP**, Dzau VJ, Gibbons G: *“Enhancement of Vascular Function by Modulation of Endogenous Nitric Oxide Production or Activity”* U.S. Patent # 6,646,006 (Filed Feb 1, 2002; issued Nov 11, 2003). This patent protects the use of L-arginine and antioxidants to enhance nitric oxide production or activity.
 18. Lin KY and **Cooke JP**: Methods for detecting asymmetric dimethylarginine in a biological sample. United States Patent No. 7,611,844 (US Provisional Patent Application N. 60/426,677 filed 11/15/2002. Appl No. 10/713,674, filed 11/13/2003, allowed 6/22/09, issued Nov 3, 2009)
 19. Trapp G, Zare RN and **Cooke JP**: Assay for asymmetrical dimethylarginine (US Provisional Patent Application). Filing Date: 2/6/2004 Appl. No.: 60/542623
 20. Fung ET, **Cooke JP**, Meng X-Y, Yip T-T, Zhang F: Biomarkers for peripheral arterial disease. US Provisional Patent Application, Serial No. 60/577,348 filed June 3, 2004 Assignee: Vermillion, Inc.
 21. **Cooke JP** and Lin KY: Modulators of Dimethylarginine Dimethylaminohydrolase and methods of use thereof (filed Nov 12 2004)
 22. **Cooke JP**, Ng M, Wu J, Chang E: Methods of Modulating Angiogenesis and screening compounds for activity in modulating angiogenesis (US Patent Application #11/521,787 filed on September 16, 2005)
 23. **Cooke JP**, Jang J, Tsao P and Heeschen C : *Nicotine in Therapeutic Angiogenesis and Vasculogenesis*. Continuation-in-part of US Patent Application #10/147,389 (filed 11-22-2005). Assignee: Stanford University. This patent protects the use of acetylcholinesterase inhibitors for angiogenesis Licensee: CoMentis.
 24. Fung ET, **Cooke JP**, Zhang F, Wilson A: A panel of biomarkers for peripheral arterial disease. US Patent Application No. 11/934,008. Filed at the USPTO on Nov 1, 2007
 25. Zhang X, Kengatharan M, **Cooke JP**, Takruri H: Topical Mecamylamine Formulations For Ocular Administration And Uses Thereof, filed 12/18/2006 (US and PCT), U.S.

- App. Pub. No. 2007/0167526 and WO 2007/075720 (PCT), Priority cases: 60/859,582, filed 11/17/2006; 60/838,605, filed 8/17/2006; 60/751,808, filed 12/19/2005.
26. **Cooke JP**, Wilson A: Beta2-microglobulin and C Reactive Protein (CRP) as biomarkers for peripheral arterial disease. Application no. 12/147,385. Filed 06/26/2008. Allowed 10/14/2011.
 27. **Cooke JP**, Heeschen C, Weis M: Methods of reducing angiogenesis (U.S. Patent No. 7,652,038 (filed May 9, 2008; Issued Jan 6, 2010).
 28. Yang W, Patel K, Ghebremariam Y, Lee J, Wong H-C, **Cooke JP** and Swartz JR: Cell-free synthesis of active reprogramming transcription factors. (WO 2011/008867, publ. Jan 20,2011)
 29. Paukshto M, **Cooke JP**, Zaitseva T, Huang N, Martin G, and Fuller G: A device and methods to guide endothelial cell assembly (filed US Patent office, Oct 2011)
 30. Paukshto M, Martin G, and **Cooke JP**: Conductive Biopolymer Implant For Enhancing Tissue Repair And Regeneration Using Electromagnetic Fields. PCT Application No. PCT/US2011/44231; Filed: July 15, 2011 Priority: U.S. Patent Application No. 61/364,759; Filed: July 15, 2010
 31. **Cooke JP**, Lee JE, Sayed N: *“Activation of Innate Immunity for Enhanced Reprogramming of Cells to Pluripotency”* (Provisional filed, US Patent office, Jan 2012)